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Abstract
Rituximab for the treatment of fatigue in primary biliary
cholangitis (formerly primary biliary cirrhosis): a randomised
controlled trial
Amardeep Khanna,1,2† Laura Jopson,1,2† Denise Howel,3
Andrew Bryant,3 Andrew Blamire,2 Julia L Newton,2
Jennifer Wilkinson,4 Alison J Steel,4 Jennifer Bainbridge,2
Renae Stefanetti,5 Sophie Cassidy,5 David Houghton5
and David E Jones1,2*
1Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK
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4Clinical Trials Unit, Newcastle University, Newcastle upon Tyne, UK
5Institute of Neuroscience, Newcastle University, Newcastle upon Tyne, UK
*Corresponding author d.e.j.jones@ncl.ac.uk
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Background: Primary biliary cirrhosis (PBC) is an autoimmune liver disease, and 50% of patients with this
disease experience fatigue. This is a debilitating symptom affecting quality of life and resulting in social
isolation, which is highlighted by patients as a research priority. PBC is characterised immunologically by
the presence of high-titre autoantibodies that are directed at the pyruvate dehydrogenase complex (PDC)
and are highly effective at blocking its energy generation function. We hypothesised that if anti-PDC
antibodies were a driver of fatigue through bioenergetic dysfunction, then the B-cell-targeting biological
agent rituximab (MabThera®, Roche Products Ltd, Welwyn Garden City, UK) might be a therapeutic option.
Objective: To assess whether or not rituximab safely improved moderate or severe fatigue in PBC patients.
Design: A Phase II, double-blind, randomised controlled trial comparing rituximab with placebo in fatigued
PBC patients. Randomisation was conducted using a web-based system. Participants received two infusions
on days 1 and 15 and were followed up at 3, 6, 9 and 12 months.
Setting: A single-centre UK study in Newcastle upon Tyne Hospitals NHS Foundation Trust.
Participants: Seventy-one participants aged ≥ 18 years with PBC and moderate or severe fatigue (score
of > 33 on the PBC-40 fatigue domain) were screened. The PBC-40 questionnaire is a fully validated
disease-specific health-related quality-of-life measure for use in patients with PBC. Fatigue, with a
maximum score of 55, is one of its six domains. Fifty-seven participants were randomised to the trial,
55 of whom reached the primary end-point assessment.
Intervention: Participants were randomised in a 1 : 1 ratio to receive either rituximab (1000 mg) or a
saline intravenous infusion (placebo) on days 1 and 15. The infusions were delivered in a double-blind
manner using the same protocol.
Main outcome measures: The primary outcome measure was the PBC-40 fatigue domain at 3 months,
assessed on an intention-to-treat basis. Secondary outcome measures included markers of bioenergetics
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function (anaerobic threshold and post-exercise muscle pH assessed using magnetic resonance imaging)
and physical activity levels. Impact on biochemical markers of liver disease severity was assessed as an
experimental outcome.
Results: Rituximab therapy was safe, with no serious adverse events linked to the drug. There was no
statistically significant difference in fatigue score at 3 months between the rituximab and placebo arms
[adjusted mean difference –0.9, 95% confidence interval (CI) –4.6 to 3.1]. However, improvement in
fatigue was observed in both arms {mean score decreasing from 41.2 [standard deviation (SD) 5.5] to 36.2
(SD 8.4) in the rituximab arm and from 43.0 (SD 5.9) to 38.1 (SD 8.7) in the placebo arm}. There was little
difference in any of the secondary outcomes between arms. However, anaerobic threshold improved
significantly in the rituximab arm (adjusted mean difference at 3 months 1.41, 95% CI 0.03 to 2.80). No
change in muscle bioenergetics characteristics was seen. A suggestive improvement in liver biochemistry
was observed.
Limitations: Recruitment was lower than the original target, leading to a reduction in study power.
A clinically significant placebo effect on PBC-40 fatigue scores was seen.
Conclusions: Rituximab is ineffective for the treatment of fatigue in unselected PBC patients despite
metabolic modulation through improvement of anaerobic threshold.
Future work: Results from the trial demonstrate that metabolic effect of rituximab is not translated into
clinical benefit. This will help to guide us to design future trials and when looking at completely
different targets.
Trial registration: Current Controlled Trials ISRCTN03978701, ClinicalTrials.gov identifier NCT02376335
and EudraCT number 2012-000145-12.
Funding: This project was funded by the National Institute for Health Research (NIHR) Efficacy and
Mechanism Evaluation programme and will be published in full in Efficacy and Mechanism Evaluation;
Vol. 5, No. 2. See the NIHR Journals Library website for further project information. Additional funding was
received from the Medical Research Council and a Department of Health and Social Care subvention.
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Plain English summary
P rimary biliary cholangitis [formerly primary biliary cirrhosis (PBC)] is a liver disease, and approximatelyhalf of the patients with this disease experience fatigue as one of the symptoms, which can significantly
affect their quality of life. PBC patients have antibodies (which are molecules produced by their immune system),
namely anti-mitochondrial antibodies. Mitochondria are parts of human cells in which energy-producing
reactions take place. Studies have shown that abnormalities in the muscle energy regulation in fatigued PBC
patients are linked to these antibodies. Rituximab (MabThera®, Roche Products Ltd) is a drug that works against
these antibodies. This drug has been in use in other conditions for over two decades. Data from pilot studies
using rituximab in fatigued PBC patients suggested some beneficial effects of the drug in symptom
improvement. Based on this background, we designed a trial to assess whether or not rituximab improved
moderate or severe fatigue in patients with PBC. We monitored safety and the tolerability of rituximab in
patients with PBC. Fifty-seven adult participants (aged ≥ 18 years) with PBC and moderate or severe fatigue
(assessed using a PBC-40 fatigue questionnaire) were recruited into the trial. They were randomised to receive
either rituximab infusion (trial drug) or saline infusion (placebo) on two occasions. They were then followed up
over a period of 12 months. Analysis of the results showed no significant difference in fatigue score at 3 months
(primary outcome) between the rituximab and placebo groups. There was also little difference in any of the
secondary outcomes between groups, although anaerobic threshold (a quantitative measure of exercise)
improved significantly in the rituximab group compared with the placebo group. A suggestive improvement in
some liver tests was observed. Rituximab was found to be safe, with no serious adverse events reported in the
patients who received the drug. We concluded that rituximab is ineffective for the treatment of fatigue in
unselected PBC patients.
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Scientific summary
Background
B-cell-depleting therapy (RITuximab) as a treatment for fatigue in Primary Biliary Cirrhosis (RITPBC) was
a Phase II randomised placebo-controlled trial targeting moderate to severe fatigue in primary biliary
cholangitis [formerly primary biliary cirrhosis (PBC)].
Primary biliary cirrhosis is an autoimmune liver disease characterised by loss of the intrahepatic bile ducts,
accompanied by progressive cholestasis. Fifty per cent of patients experience significant fatigue, a particularly
debilitating symptom affecting quality of life and resulting in social isolation. Fatigue can occur at any
point in the disease course, and its severity is unrelated to liver disease activity or degree of liver damage.
Unsurprisingly, in light of this, fatigue severity is not reduced by current first- and second-line therapy.
Given its impact and lack of response to therapy, increasing understanding of, and treatment for, fatigue
has been highlighted by patients as a priority for research. Patient support groups were actively involved in
developing the concept underpinning this trial, contributing to the protocol and supporting recruitment for
the trial. This was the first randomised controlled trial to investigate a treatment for fatigue in PBC.
Primary biliary cirrhosis is characterised immunologically by the presence of high-titre autoantibodies
directed at pyruvate dehydrogenase complex (PDC), an enzyme complex that plays a critical role in cellular
bioenergetics function-linking glycolysis and the Krebs cycle. Anti-PDC antibodies from PBC patients are highly
effective, in vitro at least, at blocking PDC function. Clinically, PBC patients exhibit both central and peripheral
elements to their fatigue. The peripheral component, likened by patients to feeling that their ‘batteries
are running down’, is significant and associated with the inability to sustain repeat muscle contraction.
Investigation of this phenomenon, using novel magnetic resonance (MR) spectroscopy approaches, revealed
marked muscle acidosis with exercise, related to mitochondrial dysfunction, and a prolongation in the time
taken for recovery of muscle acidosis following discontinuation of exercise, which was related to fatigue
severity. The degree of mitochondrial dysfunction was also related to serum anti-PDC antibody level. In
separate approaches, PBC patients have been shown to have lower anaerobic threshold levels than matched
control subjects with normal or reduced bile flow (cholestasis). Taken together, these observations point
to dysregulation of aerobic metabolism in muscle in PBC, with excessive or inappropriate utilisation of the
anaerobic lactate dehydrogenase pathway. The link between anti-PDC antibody levels and mitochondrial
dysfunction, and the capacity of anti-PDC antibodies to block PDC function (a key checkpoint in the
progression from glycolysis to the Krebs cycle in aerobic metabolism), led us to postulate that anti-PDC
antibodies are in fact the driver for the metabolic insult in PBC and that this insult underpinned fatigue.
The potential for this approach was supported by a pilot study completed in Canada that demonstrated a
beneficial action of rituximab (MabThera®, Roche Products Ltd) on fatigue in PBC.
If anti-PDC were a driver for fatigue in PBC, then the B-cell-targeting biological agent rituximab might be
regarded as a plausible therapy option. This is a hypothesis that is supported by open-label pilot data,
suggesting improvement in fatigue with this agent.
Objectives
l To assess if rituximab improved moderate or severe fatigue in patients with PBC and the sustainability
of any improvement over time.
l To assess the safety and tolerability of rituximab in patients with PBC.
l To assess the effect of rituximab on anti-PDC antibodies in PBC and on bioenergetics abnormality
potentially linked to fatigue.
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Methods
Design
This was a Phase II, double-blind, randomised controlled trial comparing rituximab with placebo in fatigued
PBC patients. Randomisation was conducted using a web-based system. Treatment allocation was kept
blinded from the patients, study assessors and investigators until study completion. Participants received
two infusions on days 1 and 15 and were then followed up at 3, 6, 9 and 12 months. The setting was a
single centre in the UK.
Participants
Seventy-one patients aged ≥ 18 years with PBC and moderate or severe fatigue (as measured by a
PBC-40 fatigue domain score of > 33) were screened and 57 participants were randomised to the trial.
The main inclusion criteria were that participants were aged ≥ 18 years with an established diagnosis of PBC
and with stable or compensated liver disease. The major exclusion criteria were inability to give consent,
alternative diagnosis of liver disease, advanced or decompensated disease, pregnancy or lactation,
immune-compromised state, malignancy, active or severe infections, demyelinating disorder and
psychiatric disorder.
Intervention
Participants in the study were randomised in a 1 : 1 ratio to receive either rituximab intravenous (i.v.)
infusion (1000 mg) on days 1 and 15 (n = 28) or saline i.v. infusion (placebo) on days 1 and 15 (n = 29).
The infusions were delivered in a double-blind manner to participants using the same protocol.
Outcome measures
The primary outcome measure was the PBC-40 fatigue domain score at 3 months, a disease-specific
quality-of-life measure. The time course of the comparison between intervention and control groups over the
12-month follow-up period was also assessed. Secondary outcome measures included an extended panel
of patient-reported outcome measures (PROMs) [including the other domains of the PBC-40 (cognitive,
itch, social, emotional and other symptoms), and tools for depressions, anxiety, sleep disturbance and
autonomic dysfunction], assessment of bioenergetics function [including anaerobic threshold assessed
using conventional cardiopulmonary exercise testing (CPET) and post-exercise muscle pH assessed using MR]
and physical activity monitoring.
Efficacy in terms of B-cell depletion was assessed using fluorescence-activated cell analysis and anti-PDC
antibodies through enzyme-linked immunosorbent assay assessment of serum anti-PDC antibody levels.
The impact on biochemical markers of liver disease severity was assessed as an experimental analysis.
Results
Rituximab therapy was safe, with no serious adverse events linked to the drug and no difference in the
adverse event profile between the rituximab and placebo groups.
Primary end point
There was no statistically significant difference in fatigue score at 3 months between the rituximab and
placebo arms [adjusted mean difference –0.9, 95% confidence interval (CI) –4.6 to 3.1]. However,
improvement was observed in both arms {with mean score decreasing from 41.2 [standard deviation (SD)
5.5] to 36.2 (SD 8.4) and from 43.0 (SD 5.9) to 38.1 (SD 8.7) in the rituximab and placebo arms,
respectively}. There was no significant difference between the two trial arms over the repeated
assessments at 3, 6, 9 and 12 months (F = 1.81; p = 0.18).
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Secondary end points
Immunological analyses suggested that rituximab was effective in mediating depletion of B-cells: its
primary proposed mode of action. No depletion was seen in the placebo arm. Complete depletion was
maintained at 6 months with gradual repopulation to 50% of the baseline level by 12 months. The
kinetics of fatigue reduction in the rituximab group mirrored the kinetics of B-cell depletion and recovery.
Reduction in the levels of anti-PDC antibody (the characteristic autoantibody of PBC) was also seen in the
rituximab (but not placebo) group. Peak reduction was seen at 6 months and this was sustained at
9 months. Reduction in total immunoglobulin, and in particular the immunoglobulin M fraction, was seen.
Again, reduction was incomplete in the rituximab-treated group and absent from the placebo group.
Additional PROMs were used to assess other aspects of the patient experience [the five non-fatigue
domains of the PBC-40 (addressing itch, cognitive, emotional, social and other symptoms), Epworth
Sleepiness Scale (daytime somnolence), Orthostatic Grading Scale (autonomic dysfunction), Cognitive
Failure Questionnaire (cognitive symptoms) and Hospital Anxiety and Depression Scale (depression and
anxiety)]. The unadjusted and adjusted differences in mean scores between trial arms showed little
difference at 3 months. The 95% CIs were generally wide, but there was no real suggestion that the
results were consistent with any clinically important differences. In contrast to fatigue, which showed
improvement in both the active drug and the placebo arms, no notable improvement in the other
measures was seen in either group. Any placebo effect was therefore restricted to fatigue, and was absent
even from the closely linked cognitive symptom domain. Physical activity levels [Euclidean Norm Minus
One (ENMO)] differed little between arms at 3 months: the adjusted mean ENMO levels were slightly lower
in the rituximab arm, but there was little indication of a large and meaningful difference.
We used a combination of MR spectroscopy of muscle and anaerobic threshold assessment using CPET to
calculate changes in pH and recovery time post exercise. In keeping with previous reports, anaerobic threshold
at baseline was low in this PBC patient group. The mean values rose in the rituximab arm from baseline to
3-month follow-up, with no change in the placebo arm. The anaerobic threshold score at 3 months was
higher in the rituximab arm than in the placebo arm (adjusted difference 1.41, 95% CI 0.03 to 2.80).
There was no apparent correlation between degree of change in anaerobic threshold and change in
fatigue over 3 months from baseline.
In keeping with our previous reported findings, the minimum pH following the specific exercise task was
highly variable among the PBC patients, with substantial acidosis seen in some patients. Minimum pH in
muscle seen following exercise was higher and the fall in pH with exercise was lower following rituximab
therapy compared with placebo. No reduction in the time taken to recover to baseline pH after exercise
and no reduction in the ‘area under the curve’ for pH (a factor combining the degree of acidosis and the
length of time taken to recover to the baseline level and an estimate therefore of degree of muscle
intracellular acid exposure) was seen in either arm. Comparison of bioenergetics outcomes between trial
arms shows that the adjusted differences in means at 3 months were all small, with relatively narrow 95%
CIs for the pH parameters.
No significant association was seen between changes in any MR parameter and change in fatigue severity.
Experimental analysis
The RITPBC trial was not designed or powered to explore the impact of the drug on liver injury; however,
the trial provided some insight into the impact of rituximab therapy in early disease, which could inform
future trials of disease-modifying therapy. Ninety-three per cent of patients in the rituximab arm had normal
alkaline phosphatase (ALP) levels at 3 months, whereas 65% had ALP levels in the normal range in the
placebo arm at 3 months. All parameters progressively returned to the baseline level by 12 months of
follow-up.
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Conclusions
The following conclusions can be drawn from this study:
l There is no evidence to support the use of rituximab for the treatment of fatigue in otherwise
unselected populations of PBC patients with moderate to severe fatigue. On average, the trial end
point of a 5-point reduction in fatigue severity was met; however, this did not significantly exceed the
effect seen with placebo.
l Trials of fatigue-modulating therapy are deliverable in PBC and are acceptable to patients (retention
was 100%). However, there is a significant issue with placebo effects that are similar in scale to those
seen in recent PBC trials of anti-itch therapy.
l Rituximab when used in PBC was safe with no disease-attributable serious adverse events.
l The bioenergetics abnormality reported previously in fatigued PBC patients and that underpinned the
trial concept was also seen in this trial.
l Anaerobic threshold was significantly improved by rituximab. Muscle bioenergetics abnormality on MR
spectroscopy was not, however, significantly improved. The capacity of muscle to handle protons and
lactate may therefore play a more important role in fatigue expression than PBC autoantibody. Future
trials of therapy for fatigue might address these aspects (exercise therapy and targeting autonomic
dysfunction).
l Although the trial was not designed or powered to explore impact on liver biochemistry, our findings
point to a positive impact of rituximab on liver function when used in patients not defined by
ursodeoxycholic acid failure.
Trial registration
This trial is registered as ISRCTN03978701, ClinicalTrials.gov identifier NCT02376335 and EudraCT number
2012-000145-12.
Funding
Funding for this study was provided by the Efficacy and Mechanism Evaluation programme of the National
Institute for Health Research. Additional funding was received from the Medical Research Council and a
Department of Health and Social Care subvention.
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Chapter 1 Introduction
Scientific background and rationale
Primary biliary cirrhosis (PBC) is a chronic liver disease affecting approximately 20,000 patients in the UK
(prevalence 35/100,000).1 In 2015, the name of the disease was changed to primary biliary cholangitis at
the request of international patient groups.2 The revised name better reflects the disease process present in
the majority of patients. The disease is characterised pathologically by inflammation within the portal tracts
in the liver and progressive loss of small intrahepatic bile ducts.3 A relatively small proportion of patients
progress, if untreated, to cirrhosis and end-stage liver disease requiring liver transplantation.4 Bile acid
therapy in the form of the first-line agent ursodeoxycholic acid (UDCA) is effective at slowing or stopping
progression to the end stage in the majority of patients, probably through a reduction of secondary liver
injury as a result of retention of cytotoxic hydrophobic bile acids occurring in the context of bile duct
loss.5–9 Up to 40% of PBC patients are under-responsive to UDCA and are at increased risk of progression
of the disease to cirrhosis.10–12 Second-line bile acid therapy in the form of obeticholic acid (a modified bile
acid that has enhanced farnesoid X receptor agonist properties that lead to reduced endogenous bile acid
synthesis) has recently been approved in the USA and Europe for use in patients showing an inadequate
response to UDCA and was approved by the National Institute for Health and Care Excellence in early 2016.13,14
The high levels of autoantibodies seen in PBC patients, strong associations with other autoimmune
diseases and pattern of immunogenetic susceptibility (which points to a key role for immune dysregulation
in the disease) all point to PBC being an autoimmune disease.15–18 It is increasingly clear, however, that the
disease is multistage in nature, with initial immune injury to the target epithelial cells lining the small
intrahepatic bile duct being followed by secondary cholestatic injury in which toxic hydrophobic bile acids
retained in the liver as a consequence of early bile duct injury cause further bile duct injury. This cycle has
the potential to be self-perpetuating.19
Fatigue: the commonest symptom in primary biliary cirrhosis
Historically, the main focus in terms of clinical impact and its treatment in PBC has been progression of
the disease to cirrhosis and, ultimately, death. In recent years, with the advent of large-scale representative
patient cohorts and validated patient-reported outcome measures (PROMs), it has become widely accepted
that there is another important aspect to patient impact: that is quality-of-life impairment related to systemic
symptoms.12,17,20–24 Although quality-of-life impairment can be significant in patients with decompensated
cirrhotic disease, this state is very uncommon in the condition, meaning that the conventional complications
of end-stage liver disease contribute relatively little to overall quality-of-life burden.25,26 In contrast, the
disutility associated with the non-stage-specific symptoms is substantial.24 Data from the very large UK-PBC
cohort have also demonstrated that the burden of impaired quality of life is age related, with younger
patients experiencing the worst symptoms and the greatest quality-of-life burden.27
The symptom reported most frequently by PBC patients is chronic fatigue, which is present in > 50% and
which has an often striking impact on patients.28–30 There are currently no effective treatments for fatigue in
PBC, with international treatment guidelines recommending only supportive treatment.31 Unsurprisingly,
given its prevalence, impact and the lack of effective treatments, fatigue is frequently identified by PBC
patients as the principal priority area for new therapy development. There has been a significant recent
increase in the understanding of the potential mechanisms that might contribute to fatigue in PBC, and
significant advances in the development of clinical tools that are able to quantify the impact of that fatigue
and that represent key tools for the study of fatigue pathogenesis and, critically, treatment. The key
advance in this regard has been the development of the PBC-40, a patient-derived, disease-specific,
quality-of-life measure that has become the standard measure used in all clinical trials.14,21,32
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Fatigue severity in PBC is not associated with the stage of the disease and is frequently seen in its most
severe form in patients with early disease and a seemingly very good prognosis from the point of view
of risk of death from their liver disease.12,28,33 This can result in a discrepancy between the physician’s
and patient’s perception of how well the patient is doing, with the former seeing a level of liver injury
suggesting a good prognosis and the latter focusing on their severe fatigue.30 Furthermore, there is no
evidence to suggest that either current first- (UDCA) or second-line therapy has any impact on fatigue
severity.12,14 As prognostic management gets better in PBC, so the contrast between length of life and
quality-of-life improvement will become increasingly marked.
The issue of the role played by depression in the expression of fatigue in PBC is a controversial one, with
many patients being clinically labelled as having depression simply because they are fatigued, making
the association self-fulfilling. Although depressive problems can clearly occur in fatigued PBC patients
(frequently as a consequence of the considerable limitation to lifestyle that they experience), and positive
coping strategies are an important part of managing fatigue, overt depressive illness is actually a rare cause
of fatigue in PBC.34,35 In fact, in most fatigued PBC patients it is peripheral, activity-limiting fatigue that
predominates.36 Fatigue in PBC can be associated with significant fatigue disturbance (in particular daytime
somnolence) and autonomic dysfunction (particularly in the form of baroreflex sensitivity loss). The extent
to which these associations reflect causes or consequences of chronic fatigue is unclear at present.1
The scale of the problem of fatigue in primary biliary cirrhosis
Population-based studies undertaken using the PBC-40, which contains a fully validated fatigue domain,
have suggested that > 50% of PBC patients across the UK experience moderate or severe fatigue, with
> 20% experiencing sustained severe fatigue (≈4000 patients nationally), with a profound impact on life
quality.12,24,27 Fewer than 20% of severely fatigued patients are able to work, with the majority of this group
dependent on state benefits for income. Severe fatigue also causes social isolation in people who lack the
energy to leave their house and interact with others, a particular issue among younger patients.24 Severely
fatigued PBC patients also frequently have problems with their ability to care for others (90% of PBC patients
are female and they often have young children and/or dependent elder relatives themselves), with cases of
Meals on Wheels being provided for the children of socially isolated, severely fatigued PBC patients being far
from uncommon. The management of severe fatigue in PBC, which is currently largely supportive, is a major
draw on NHS budgets (the trial investigators are currently following up > 150 severely fatigued patients with,
typically, monthly clinic follow-up).26,31 Severe fatigue is also a frequent driver for patients seeking liver
transplantation, although the evidence to suggest that there is any benefit from transplantation for PBC
fatigue is limited.25,37 Treatment able to reduce the impact of severe fatigue in PBC would transform the lives
of patients and their families, substantially reduce the costs of NHS treatment (the costs of follow-up and
supportive management of fatigued patients and the costs of transplantation where the indication is
advanced liver disease but the patient driver is fatigue) and, importantly, the costs to society of this socially
isolated, economically unproductive and dependent group of people.38
Bioenergetic abnormality is frequent in primary biliary cirrhosis and is associated
with fatigue
Primary biliary cirrhosis patients’ descriptions of fatigue emphasise an inability to sustain physical activity
and concepts related to ‘energy’ or ‘power’ depletion (a further group describe ‘brain fog’, which is
associated with significant cognitive symptoms). Furthermore, on repeat testing, handgrip strength reduces
rapidly in fatigued PBC patients and is associated with perceived fatigue severity.36 More recently, using
magnetic resonance (MR) spectroscopy approaches, we demonstrated (and replicated in a second cohort)
the presence of significant peripheral muscle bioenergetic abnormality in PBC patients.39,40 Abnormality is
also present in cardiac muscle, suggesting the presence of a broadly based bioenergetic abnormality.41
These studies have suggested the presence of abnormality in mitochondrial function (in particular, recovery
response to the energetic burden of repeat exercise) and a tendency for excessive intramuscular acidosis
during, and in the recovery from, exercise. Intramuscular acidosis in a well-recognised contributing factor
to muscle fatigue in the general population.42
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In PBC, the length of time that significant acidosis is present in muscle and the rate of recovery from that
acidosis are strongly associated with the severity of fatigue that patients experience.43–45 The cumulative effect
of a pro-acidotic effect and delays in recovery is well demonstrated using an integrative approach exploring
the ‘area under the curve’ (AUC) for pH during exercise and in the recovery from exercise, which gives a
measure of the scale of excess proton exposure in PBC and its association with fatigue (Figure 1). Recent
studies using metabolomics approaches have shown lactate accumulation within tissues in PBC.46 Our own
unpublished study of anaerobic threshold in PBC patients (compared with age- and sex-matched patients
with primary sclerosing cholangitis and sedentary control subjects), assessed using an incremental exercise
approach, shows significantly lower anaerobic threshold values in PBC that cannot be accounted for by either
deconditioning or by the presence of cholestatic liver disease per se.47 These observations further support
the presence of bioenergetic abnormality in PBC and critically do so using complementary experimental
approaches. Taken together, these studies all point to excessive utilisation of anaerobic metabolism pathways
in muscle in PBC [metabolism of pyruvate to lactate via the actions of lactate dehydrogenase rather than to
acetyl coenzyme A via the actions of pyruvate dehydrogenase (PDH)]. This leads, we hypothesised, to excessive
and inappropriate lactic acid accumulation in muscle in PBC and, in the absence of an effective adaptive
response to it, fatigue. In this model, capacity to adapt to acid load is a physiological variant that is naturally
protective from fatigue in some people and that can be induced by exercise therapy. The critical question is
‘why do PBC patients seemingly overutilise anaerobic metabolism pathways and how can we use that
knowledge to treat their fatigue?’.
Primary biliary cirrhosis is characterised by autoimmune responses directed at
bioenergetic enzymes
The obvious link between PBC as an autoimmune disease and PBC as a disease characterised by
overutilisation of anaerobic pathways and associated fatigue is the characteristic autoantibody response
in PBC, which is directed at PDH, the enzyme that controls entry into aerobic metabolism pathways.
High-titre anti-PDH antibodies are present in > 95% of PBC patients and are able to fully block PDH
function during in vitro assays.48,49 The basis of this inhibitory function (which is so consistent that one of
the assays for anti-PDH in PBC utilises inhibitory capacity as a readout) is the specific reactivity of anti-PDH
antibodies with a lipoic acid cofactor present on the E2 and E3 binding protein components of PDH, to
which the principal autoepitopes have been localised, which is essential for enzymatic function and which
is blocked by antibody binding.50
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FIGURE 1 Area under receiver operating characteristic (AUROC) changes in pH vs. recovery time following exercise.
Blue is normal, green is non-fatigued PBC patients and black is fatigued PBC patients.
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Targeting autoreactive responses in primary biliary cirrhosis as a potential therapy
for fatigue
Three strands of evidence support a potential direct role for anti-PDH antibody responses in bioenergetic
abnormality and fatigue in PBC.
1. The mitochondrial bioenergetic abnormality in PBC is directly associated with the level of serum
anti-PDH antibody, with median anti-PDH titre being > 200-fold higher in patients with mitochondrial
bioenergetic abnormality than in those without (9.9 × 105 vs. 4.1 × 103; p < 0.05).39 At least part of the
anti-PDH autoantibody response in PBC is directed at the lipoate component of PDH and is reactive
with free lipoic acid in the circulation.50 Given that free lipoic acid plays an important role in regulating
PDH function (it activates PDH through inhibition of PDH-kinase), its consumption by autoantibody in
PBC represents one potential mechanism for the bioenergetic effect of that antibody.51
2. Patients who are anti-PDH antibody positive but who have normal liver function (‘pre-PBC’ patients)
experience fatigue of the same severity as ‘classic’ PBC patients, suggesting that fatigue is a feature of
the presence of anti-PDH rather than PBC per se.52
3. Fatigue is typically not improved following liver transplantation in PBC.38,53 Anti-PDH universally remains
present at unchanged levels following liver transplantation in PBC.
A direct role for anti-PDH antibody in bioenergetic abnormality and fatigue was the justification for
exploration of therapies able to deplete the B-cell compartment, exemplified by the anti-CD20 antibody
rituximab (MabThera®, Roche Products Ltd) as a treatment for fatigue in PBC.
Rituximab in primary biliary cirrhosis
A pilot study performed in Canada exploring the use of rituximab in PBC (in 13 patients) provided proof of
concept, showing that the agent is safe and well tolerated in patients and is associated with a clinically
significant reduction in fatigue.54 Fatigue severity was assessed using the Fatigue Severity Scale (potential
range 9–63 points), with a fall being seen from pre treatment (median 36 points, range 11–59 points) to
post treatment (median 29 points, range 12–55 points). Taking into account the floor value for the Fatigue
Severity Scale, this represents a median fall in fatigue severity over 6 months of 26%. This compares with
our own case–control study of fatigue in PBC, which suggests that fatigue severity in age- and sex-matched
normal controls is 30% lower than in PBC patients, suggesting the potential for rituximab therapy to return
PBC patients to close to normal with regard to their perceived fatigue.28 However, this pilot study did not
attempt to explore the mechanism of the effect and, as it did not use severe fatigue as an inclusion
criterion, the extent of possible improvement for such patients is unclear. Moreover, the study was not
optimised for the study of fatigue (fatigue was a secondary outcome and only some of the patients who
participated had fatigue, potentially underestimating the clinical effect). Other evaluations of rituximab in
PBC have focused exclusively on disease severity as an end point.55 Both studies showed a sustained
reduction in anti-PDH antibody levels of all isotypes, supporting the concept that rituximab has a beneficial
effect on fatigue through depletion of PDH-reactive antibody. In all studies in PBC to date, rituximab has
been found to be well tolerated.
Study objectives
The importance of severe fatigue in PBC and the current lack of treatments, the strong theoretical basis
for the approach and the supportive pilot trial proof-of-concept data all, we believe, justified a formal
clinical trial of rituximab targeting fatigue in PBC. Secondary outcome measures included an extended
panel of patient-reported outcome measures (PROMs), [including the other domains of the PBC-40
markers (cognitive, itch, social, emotional and other symptoms), and tools for depressions, anxiety, sleep
disturbance and autonomic dysfunction], assessment of bioenergetics function [including anaerobic
threshold assessed using conventional cardiopulmonary exercise testing (CPET) and post-exercise muscle
pH assessed using MR] and physical activity monitoring.17,56,57
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The primary objective of the study was to undertake a placebo-controlled trial to assess the efficacy of
rituximab as a treatment for moderate to severe fatigue in PBC.
The secondary objectives of the study were to explore:
l the mechanism of any observed improvement in fatigue severity in relation to the identified associated
mechanisms of fatigue related to bioenergetics abnormality in the cardiovascular system and peripheral
muscle function in PBC
l the mechanisms underpinning physiological abnormality in PBC and their relationship to fatigue
through the study of the baseline data for the study cohort
l any effects of rituximab therapy on biochemical parameters of disease severity in PBC.
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Chapter 2 Methods
The text in this section is reproduced from the trial protocol we published in Jopson et al.38 This is anOpen Access article distributed in accordance with the Creative Commons Attribution Non Commercial
(CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially,
and license their derivative works on different terms, provided the original work is properly cited and the use is
non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
Study conduct
This single-centre randomised controlled trial was conducted in the clinical research facility of the
Newcastle upon Tyne Hospitals Foundation Trust, commencing 1 October 2012.38 The final study visit was
on 12 September 2016. The study was conducted in accordance with the principles of Good Clinical
Practice (GCP) and received a favourable ethics opinion from the National Research Ethics Service
Committee North East – Newcastle & North Tyneside 1 (12/NE/0095) on 16 May 2012 and a clinical trial
authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA) on 15 August 2012.
The trial was managed through the Newcastle Clinical Trials Unit (NCTU) with a Trial Management Group,
together with an independent Trial Steering Committee (TSC) and Data Monitoring and Ethics Committee
(DMEC). Monitoring was performed by NCTU and the trial was audited by the sponsor, the Newcastle
upon Tyne Hospitals NHS Foundation Trust.
The clinical trial protocol has been published (https://njl-admin.nihr.ac.uk/document/download/2005806;
accessed September 2017) and the statistical analysis plan (see Report Supplementary Material 1) was
finalised prior to the final analyses. All participants provided written informed consent prior to screening.
Patient and public involvement
Fatigue was identified by our patient group as a major research priority area. LIVErNORTH and the PBC
Foundation were involved in the development of the trial concept and protocol. The final protocol was
seen and approved by the patient groups. A patient representative (from LIVErNORTH) was a member of
the TSC. The patient groups were updated throughout the course of the trial and played an important role
in increasing awareness of the trial and thus in recruitment.
Trial design
This was a Phase II, single-centre, randomised controlled, double-blinded trial comparing rituximab with
placebo in fatigued primary biliary cholangitis (cirrhosis) patients over 12 months.38 Randomisation was in
a 1 : 1 ratio.
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Participants
Participants were all patients with a clinical diagnosis of definite or probable primary biliary cholangitis
(cirrhosis); this was established using recognised epidemiological criteria:
l cholestatic liver biochemistry at disease outset [defined as elevation in the serum alkaline phosphatase
(ALP) level or gamma-glutamyl transpeptidase (GGT)]
l associated autoantibody [anti-mitochondrial antibody (AMA) or PBC-associated anti-nuclear antibody by
immunofluorescence or anti-PDH, anti-Gp210 or anti-Sp100] at a titre of ≥ 1 : 40
l diagnostic or compatible liver biopsy.
Patients exhibiting all three criteria are defined as having definite PBC. Patients with two of the three
criteria probably have PBC. Clinical practice has moved away from using liver biopsy to confirm diagnosis
(because of the diagnostic accuracy of the combination of the other two parameters, which exceeds 95%),
so the majority of patients in any clinical cohort fall into the probable disease category. Patients in whom
ALP and GGT levels return to normal with therapy retain their diagnostic status, as current therapy
approaches are disease suppressive not curative and biochemical deterioration is inevitable with universal
discontinuation of therapy.
Inclusion criteria
l Patient had capacity to consent and provided written informed consent for participation in the study
prior to any study-specific procedures.
l Moderate or severe fatigue as assessed using previously designated cut-off points of the PBC-40
fatigue domain (i.e. fatigue domain score of > 33).
l Presence of AMA (anti-PDH antibody) at a titre of > 1 : 40.
l Adequate haematological function (haemoglobin level of > 9 g/l), absolute neutrophil count of
> 1.5 × 109/l and platelet count of > 50 × 109/l.
l Bilirubin level of ≤ 50 μmol.
l International normalised ratio ≤ 1.5.
l Child–Pugh score of < 7.
l Eastern Cooperative Oncology Group performance status of < 2.
l Adequate renal function: Cockcroft–Gault estimation of > 40 ml/minute.
l Women of childbearing potential had a negative pregnancy test prior to study entry and were using an
adequate contraception method, which was continued for 3 months after completion of treatment.
Acceptable forms of effective contraception included established use of oral, injected or implanted
hormonal methods of contraception:
¢ placement of an intrauterine device or intrauterine system
¢ barrier methods of contraception – condom or occlusive cap (diaphragm or cervical/vault caps) with
spermicidal foam/gel/film/cream/suppository
¢ male sterilisation (with the appropriate post-vasectomy documentation of the absence of sperm in
the ejaculate)
¢ true abstinence – when this was in line with the preferred and usual lifestyle of the subject
¢ aged ≥ 18 years.
Exclusion criteria
l Advanced or decompensated disease (variceal bleed, hepatic encephalopathy or ascites).
l History or presence of other concomitant liver diseases (including hepatitis due to hepatitis B virus or
hepatitis C virus or evidence of chronic viraemia on baseline screening), primary sclerosing cholangitis
or biopsy-proven non-alcoholic steatohepatitis).
l Average alcohol ingestion of > 21 units per week (for males) or > 14 units per week (for females).
l Chronic sepsis or intercurrent condition likely to predispose the patient to chronic sepsis during the study.
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l Previous treatment with B-cell-depleting therapy.
l Previous history of aberrant response or intolerance to immunological agents.
l Presence of significant untreated intercurrent medical condition itself associated with fatigue.
l Presence of significant risk of depressive illness [Hospital Anxiety and Depression Scale (HADS) score
indicating cosiness].
l Current statin therapy or statin use within 3 months of enrolment.
l Ongoing participation in other clinical trials or exposure to any investigational agent 4 weeks prior to
baseline or within five or fewer half-lives of the investigational drug.
l Major surgery within 4 weeks of study entry.
l Vaccination within 4 weeks of study entry; patients requiring seasonal flu or travel vaccines will be
required to wait a minimum of 4 weeks post vaccination to enrol in the study.
l Pregnant or lactating women.
l Psychiatric or other disorder likely to have an impact on informed consent.
l Patient was unable and/or unwilling to comply with treatment and study instructions.
l Any other medical condition that, in the opinion of the investigator, would interfere with safe
completion of the study.
l Hypersensitivity to the active substance (rituximab) or to any of the excipients [sodium citrate, polysorbate 80,
sodium chloride, sodium hydroxide, hydrochloric acid and water (for infusion)] or to murine proteins.
l Active, severe infections (e.g. tuberculosis, sepsis or opportunistic infections).
l Known human immunodeficiency virus infection.
l Clinical history of latent tuberculosis infection unless the patient had completed adequate
antibiotic prophylaxis.
l Aspartate transaminase (AST)/alanine transaminase (ALT) levels four times above the upper limit of normal.
l Severe immunocompromised state.
l Severe heart failure (New York Heart Association class IV) or severe uncontrolled cardiac disease.
l Malignancy (other than basal cell carcinoma) within the last 10 years.
l Demyelinating disease.
l Previous participation in this study.
l Any contraindication to rituximab therapy not covered by other exclusions.
Withdrawal criteria
The study protocol required that the study drug be discontinued if:
l the participant developed elevated serum ALT/AST levels four times above normal limits for each
local laboratory
l the participant decided they no longer wished to continue
l cessation of study drug was recommended by the investigator.
Participants had the right to withdraw from the study at any time for any reason and without giving a
reason. The investigator also had the right to withdraw patients from the study drug in the event of
intercurrent illness, adverse events (AEs), serious adverse events (SAEs), suspected unexpected serious
adverse reactions (SUSARs), protocol violations, cure, administrative reasons or other reasons. If a patient
decided to withdraw from the study, all efforts were made to report the reason for withdrawal as
thoroughly as possible. If a patient withdrew from the study drug only, efforts were made to continue to
obtain follow-up data (with the permission of the patient).
Participants who wished to withdraw from study medication were asked to confirm whether or not they
were still willing to provide:
l study-specific data at follow-up visits 5–19 [https://njl-admin.nihr.ac.uk/document/download/2005806
(p. 33); accessed September 2017]
l end-of-study data as per visit 19, at the point of withdrawal
l questionnaire data collected as per routine clinical practice at annual follow-up visits.
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If participants agreed to any of the above, they were asked to complete a confirmation of withdrawal form
to document their decision.
Participants withdrawing from the study after receiving the second infusion were not replaced. In practice,
all seven withdrawals from the study were replaced prior to study drug administration.
Setting
All screening, consent, treatment and follow-up assessments requiring patient attendance took place at
the clinical research facility at the Royal Victoria Infirmary in Newcastle. Data recording took place in the
same setting.
Screening and recruitment processes
l Information about the study was widely disseminated via all relevant patient groups as part of our
patient and public involvement activity and through the Newcastle Clinical Service.
l Potential participants were initially identified through routine clinic outpatient appointments by their
treating physician in the hosting NHS trust [the principal investigator (PI) or other member of the
research team with documented, delegated responsibility]. Once the trial was under way, participant
identification centres (PICs) were established across the region, allowing local-level identification
of possible participants. During the course of the trial, the UK-PBC Stratified Medicine Programme
(www.UK-PBC.com; accessed September 2015) was established; this developed a national database of
PBC patients with phenotyping data and, if given, consent to be approached about follow-on studies
(including trials), which were relevant given the patient phenotype. This approach identified potential
participants, both in the host NHS trust and in PICs, aiding recruitment and opening up access to
patients from across the UK. For patients who were identified through either PICs or the UK-PBC
platform, all screening, recruitment and trial-related activity still took place at the single trial centre.
l In all cases, eligible participants were invited to participate by their consultant and the study was
explained to them. A study patient information sheet was provided and the participants had a
minimum of 48 hours to consider the information before giving written informed consent.
l The chief investigator or member of the research team with documented, delegated responsibility
witnessed, signed and dated the written informed consent form.
l Patients were then invited to participate in the formal screening process.
l An eligibility screening form was completed by the investigator to document fulfilment of the entry
criteria for all patients considered for the study and subsequently included or excluded. The log also
ensured that potential participants were approached only once.
l The original signed consent form was retained in the investigator site file, with a copy in the clinical
notes and a copy provided to the participant. The participant specifically consented for their general
practitioner to be informed of their participation in the study.
l The right to refuse to participate without giving reasons was respected.
l Arrangements were in place for translation for potential participants who were non-English speaking.
In practice, this option was not required.
l The screening assessments had to occur within the 4-week period prior to the baseline visit. If there
was a delay beyond 4 weeks for any reason, patients underwent rescreening.
Intervention
The study intervention consisted of two treatments administered on study days 1 and 15, with patient
conditioning immediately prior to each treatment. The protocol required a minimum interval of 2 weeks
between the two treatments. A 2-day visit window was allowed for each dispensing visit. Study medication
was prescribed by a study clinician in accordance with the protocol and administered to the patient by
clinical staff according to local pharmacy policy. All interventions were administered in the presence of a
METHODS
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clinician. All participants had been encouraged to have adequate oral hydration in the 24 hours prior to
attendance. Resuscitation equipment was immediately available during the infusion period. Blood pressure,
heart rate and temperature were monitored during the infusions. Participants remained under observation
in the clinical research facility for at least 2 hours after the infusion.
All unused study medication was stored in pharmacy until the end of the study, or until the trial manager
had completed appropriate reconciliation. Documentation of prescribing, dispensing and return of study
medication was maintained for study records.
Experimental intervention: rituximab therapy
The investigational medicinal product (IMP) used in the clinical trial was 1000 mg of intravenous (i.v.)
rituximab (MabThera). This product was approved by the European Agency for the Evaluation of Medicinal
Products (marketing authorisation number EU/1/98/067/002). The licence holder of MabThera is Roche
Products Ltd. The product was supplied as vials containing 500 mg of rituximab at a concentration of
10 mg/ml. Supplies of rituximab were stored in a refrigerator at between 2 °C and 8 °C in a secure location
in their original packaging in order to protect them from light. Supplies of rituximab were labelled as IMP in
accordance with regulatory requirements. Storage and supply of the rituximab was delegated to the local
pharmacy at the trial centre. Rituximab was released for use in the study once all the appropriate regulatory
and governance approvals were in place. Patients randomised to receive rituximab therapy were given
treatment at the infusion rates recommended for rheumatoid arthritis (RA) patients (i.e. for the first infusion
at an initial rate of 50 mg/hour; after the first 30 minutes the rate could be increased in increments of
50 mg/hour every 30 minutes to a maximum rate of 400 mg/hour). Second doses were infused at an initial
rate of 100 mg/hour and increased by 100 mg/hour at 30-minute intervals to a maximum of 400 mg/hour.
Rituximab has a shelf life of 30 months. The prepared infusion solution of rituximab (MabThera) was
physically and chemically stable for 24 hours at temperatures between 2 °C and 8 °C and subsequently
for 12 hours at room temperature. Further details can be found in the MabThera Summary of Product
Characteristics [https://njl-admin.nihr.ac.uk/document/download/2005806 (p. 56)].
Control intervention: placebo infusion
Patients randomised to receive placebo received conditioning in addition to the control saline infusion.
The control infusion was delivered in a double-blind manner to participants using the same placebo that
was used in our RA studies, under the supervision of a clinician (as per the clinical research facility protocol).
Conditioning
In line with recommendations for the administration of rituximab in other conditions, patients received
a conditioning regimen prior to the infusions of study medication on days 1 and 15. Given that this
was a double-blinded trial, both arms received the conditioning regimen. This conditioning regimen was
administered 30 minutes prior to infusion of study medication and to all patients, to maintain the double
blind. The conditioning regimen comprised 1 g of paracetamol orally, 10 mg of i.v. chlorpheniramine and
100 mg of i.v. methylprednisolone. The paracetamol, chlorpheniramine and methylprednisolone were
sourced locally.
Adverse reactions during treatment administration
During the infusion, patients were clinically monitored for the onset of clinical features of infusion-related
reactions (IRRs), the most common AEs in rituximab usage.
The protocol stated that patients who developed evidence of severe IRRs, especially severe dyspnoea,
bronchospasm or hypoxia, would have the infusion interrupted immediately, with restart of the infusion
(at not more than half the rate at which the reaction took place) not taking place until complete resolution
of all symptoms and normalisation of laboratory values and chest radiographic findings. If the same severe
adverse reactions (ARs) occurred for a second time, the treatment would be stopped. Such reactions were
not observed in the study and this protocol was therefore not invoked.
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Mild or moderate IRRs were addressed by halving the rate of infusion. The infusion rate was increased
again on improvement of symptoms. Paracetamol and/or non-steroidal anti-inflammatory drugs were
allowed for the symptomatic management of IRRs.
Concomitant medication
Concomitant therapies were managed as per the MabThera Summary of Product Characteristics. A
complete listing of all concomitant medication received during the treatment phase was recorded in the
case report form (CRF).
For patients who were receiving UDCA therapy, the dose of UDCA could not be changed during the
patients’ 12-month participation in the study. No other disease-modifying agents could be introduced
during the trial. Therapy aimed at reducing pruritus and its impact could be introduced if unavoidable at
the discretion of the investigators; however, this proved unnecessary.
Live vaccines could not be administered during the study (see Exclusion criteria).
Outcomes
Primary outcome measure
The primary outcome variable was fatigue severity in PBC patients, assessed at 3 months using the fatigue
domain of the PBC-40: a fully validated, psychometrically robust, disease-specific quality-of-life measure.21
Secondary outcome measures
The following secondary outcome measures were prespecified:
l The PBC-40 domain scores covering itch, cognitive, emotional, social and other symptom domains
at 3, 6, 9 and 12 months.
l Physical activity assessed using 7-day physical activity monitoring.
l Perceived fatigue severity assessed using a self-completion fatigue diary.
l Daytime somnolence [as assessed using the Epworth Sleepiness Scale (ESS)57], vasomotor autonomic
symptoms [assessed using the Orthostatic Grading Scale (OGS)58] and functional status [assessed using
Patient-Reported Outcomes Measurement Information System Health Assessment Questionnaire
(PROMIS HAQ), incorporating the Cognitive Failure Questionnaire (COGFAIL)29]. Reduction in depressive
and anxiety-related symptoms was assessed using the HADS.59
l Serum anti-pyruvate dehydrogenase complex (PDC) antibody levels assessed using enzyme-linked
immunosorbent assays (to confirm whether or not any clinical effect is directly related to antibody
modulation).60,61
l Peripheral muscle bioenergetic function on exercise (to confirm whether or not any clinical effect was
directly related to effects on muscle bioenergetic function). Approaches used included MR spectroscopy
assessment of muscle pH change during a fixed exercise protocol, time taken for recovery of pH to
baseline following exercise, AUC for pH (a measure of total muscle pH exposure with exercise) and
anaerobic threshold assessed using cardiopulmonary exercise testing (CPET).39,40,47
Exploratory end points
l Biochemical parameters associated with severity of the liver disease in PBC (ALP), ALT, bilirubin and albumin.
l Serum immunoglobulins (Igs) [total Ig, immunoglobulin G (IgG) and immunoglobulin M (IgM)].
During the course of the study, a continuous variable model for the prediction of outcomes in PBC was
described and validated. This used routinely collected clinical data and could be incorporated into the
protocol as exploratory end points.62 Concern had also developed around second-line therapeutics in
PBC and cardiovascular risk related to lipids. In the light of these changes, the following exploratory
end point was added during the study:
¢ blood lipid levels.
METHODS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
12
Experimental assessments
Quality-of-life and symptom assessment tools
Fatigue severity for the primary end point was assessed using the PBC-40 fatigue domain. This is a
validated, disease-specific and patient-derived quality-of-life measure. The fatigue domain score ranges
from 11 to 55 (11 items scored 1–5), with higher values denoting worse fatigue.
Other symptom severity was assessed by the relevant domain of the PBC-40 (itch, cognitive, social,
emotional and other symptoms). Functional status was assessed using the PROMIS HAQ to assess function.
The PROMIS HAQ measures the functional and physical ability of the participants (covering, dressing,
arising, eating, walking, hygiene, reach, grip and activity). The score is on a 0–100 scale with higher scores
indicating worse functional ability. Anxiety and depression were assessed by HADS score (range 0–42).
Daytime somnolence was assessed using the ESS (range 0–24), vasomotor autonomic symptoms using the
OGS (range 0–20) and cognitive functionality using COGFAIL (range 0–100), where higher scores indicate
worse outcome for all cases.
Fatigue diaries
Participant-held diaries were used to gather qualitative information on symptoms and functional ability. The
diaries measured fatigue using a scale of 1–6 (1 = no fatigue and 6 = extreme fatigue). Participants were
asked to complete the diaries six times during the study. They completed the diaries for a period of 1 week
during the first week of each month at baseline and 1, 3, 6, 9 and 12 months. Participants returned the
diaries at their final visit.
Magnetic resonance spectroscopy
Magnetic resonance data relating to muscle energetics and pH were acquired at baseline and at 12 weeks
using a 3-T Intera Achieva scanner (Philips, Best and NL; Philips Medical System, Andover, MA, USA).
The steps used for acquisition and analysis have been described, in detail, in published protocols.39,40 In
summary, this involved controlled plantarflexion using a purpose-built exercise apparatus developed for
operation within the MR imaging scanner. Participants performed two 180-second bouts of plantarflexion
contractions at 25% and then at 35% of maximal voluntary contraction, with each bout preceded by
60 seconds of rest and followed by 390 seconds of recovery. Phosphorous spectra were collected at
10-second intervals. The minimum pH seen in the exercise and recovery period, the time required post
exercise for pH to return to within 0.01 units of baseline levels (calculated as the sum for each individual
for the three bouts to form a total pH recovery time) and the mean AUC for pH for the three exercise
episodes, which reflected total acid exposure, were calculated.
Anaerobic threshold
Anaerobic threshold was assessed using conventional CPET. Participants cycled on a stationary ergometer
(Lode BV, Groningen, the Netherlands) at between 60 and 70 revolutions per minute. The test was
terminated either voluntarily by the participant or when they were unable to maintain a pedal frequency of
60 revolutions per minute. Expired air was collected at rest and during exercise using a breathing mask
and analysed online using a gas analysis system (MetaLyzer II, CORTEX Biophysiks GmbH, Walter-Kohn,
Germany). Anaerobic threshold was determined using the computerised v-slope method at baseline and
at the 12-week follow-up.
Physical activity levels
Participants completed physical activity monitoring using wrist-worn tri-axial GENEActiv accelerometers
(Activinsights Ltd, Cambridgeshire, UK). The accelerometer was worn continuously on the right wrist
for a period of 7 days in free-living conditions. Raw accelerometer data were processed in R studio
(www.cran.r-project.org; accessed February 2017) using R-package GGIR version 1.2.8 (The R Foundation
for Statistical Computing, Vienna, Austria). Patients were included in the analysis if they had worn the
monitor for a minimum period of 5 days (with at least one of these days at the weekend). Only days with
at least 22 hours of valid data were retained for further analysis. The first and last days of the raw
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accelerometer measurement were excluded as they were influenced by the monitor distribution and
collection procedure.
Following data processing and the exclusion of patients who did not meet the wear-time criteria, the
average magnitude of wrist acceleration was calculated via metric Euclidean Norm Minus One (ENMO)
as previously described.63 The output from metric ENMO is in mg (1 mg = 0.001 g = 0.001 × 9.8 m/s2
= 0.001 × gravity). In addition, the average acceleration (mg) during the most active 5-hour period of each
day was assessed pre versus post intervention.
Immunology
Quantification and phenotyping of total B-cell populations and B-cell subsets was undertaken using a
standard fluorescence-activated cell analysis-based approach. Total B-cell levels in peripheral blood were
evaluated using a direct immunofluorescence reagent (Fast Immune™ CD19/CD69/CD45, BD Biosciences,
San Jose, CA, USA).
Anti-PDH antibody total and individual isotype levels were studied on day 0 and at the primary end point
(12 weeks after therapy), using a well-established enzyme-linked immunosorbent assay developed within
our research group.61
Biochemistry and haematology
Biochemical (liver biochemistry, electrolytes and lipids) and haematological (platelet count) assessments
were undertaken using the routine clinical laboratories at the research centre. These are quality-assured
clinical parameters. The UK-PBC risk score was calculated using the published formula.62 The values
generated are percentage risks of death from liver-related causes or need for liver transplant at 10 years.
Randomisation
Randomisation was conducted by the NCTU web-based system in a 1 : 1 ratio using random-permuted
blocks with random block length. The randomisation system generated a treatment number for each
participant, which linked to the corresponding allocated study drug. The treatment number was then
documented by the investigator on the trial prescription to ensure that the study pharmacist dispensed the
correct study medication.
Patients in the study were randomised to receive either:
l rituximab therapy on days 1 and 15 (study drug) or
l placebo (normal saline) on days 1 and 15 (control).
Patients could be randomised into the study only by an authorised member of staff at the study research
site, as detailed on the study delegation log. Patients could be randomised into the study once only.
Blinding
Assignment to either the rituximab or placebo arm was blinded to both the participant and investigators/assessor.
A code-break list was kept in the pharmacy and could be accessed only in an emergency (preferably with
authorisation from the chief investigator). If the code was broken, details including the participant number,
who broke the code, why and when were recorded and maintained in the site file. Code breaks were not
routinely opened for participants who completed study treatment. One patient in the placebo arm was
unblinded during the course of the study for emergency medical reasons (a SAE). The patient remained blinded.
METHODS
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Data management and monitoring
Study data were entered into a paper CRF and then uploaded by the data manager into the MACRO
database system (Elsevier Ltd).
The study was managed through the NCTU. The Trial Management Group included the chief investigator/
PI, senior trial manager, trial manager, trial statistician, database manager, clinical research fellow and
other members of the trial team when applicable. NCTU provided day-to-day support for the site and
provided training through the site initiation visit and routine monitoring visits. The PI was responsible for
the day-to-day study conduct at the site.
Quality control was maintained through adherence to sponsor standard operating procedures, NCTU
standard operating procedures, Newcastle Magnetic Resonance Centre standard operating procedures, the
study protocol, the principles of GCP, the Research Governance Framework and clinical trial regulations.
Data Monitoring and Ethics Committee
An independent DMEC was appointed, the terms of reference of which were governed by a signed DMEC
charter. It consisted of an independent chairperson, an independent expert clinician and an independent
statistician and was convened to undertake independent review. The purpose of this committee was to
monitor efficacy and safety end points. Only the independent DMEC members and the unblinded
statistician had access to unblinded study data. The committee met eight times during the study.
Trial Steering Committee
A TSC was established to provide overall supervision of the study, the terms of reference of which were
governed by a signed TSC charter. The TSC consisted of an independent chairperson, an independent
clinician, an independent consumer representative, the chief investigator/PI, senior trial manager, trial
manager and trial statistician. Representatives of the sponsor were invited to all TSC meetings. The
committee met eight times during the study.
Study monitoring
Monitoring of study conduct and data collected was performed by a combination of central review and
site monitoring visits to ensure that the study was conducted in accordance with GCP, the protocol and
clinical trial regulations. Study site monitoring was undertaken by the trial manager. The main areas of
focus included consent, SAEs, essential documents in the investigator site file and drug accountability
and management.
Site monitoring included the following:
l All original consent forms were reviewed as part of the study file (the presence of a copy in the patient
hospital notes was confirmed for 20% of participants).
l All original consent forms were compared against the study participant identification list.
l All reported SAEs were verified against treatment notes/medical records (source data verification).
l Essential documents were accessible in the investigator site file.
l Source data verification of primary end point data and eligibility data was undertaken for 20% of
participants entered in the study.
l Drug accountability and management was checked; an unblinded monitor conducted pharmacy
monitoring visits.
Central monitoring included the following:
l All applications for study authorisations and submissions of progress/safety reports were reviewed for
accuracy and completeness, prior to submission.
l All documentation essential for study initiation was reviewed prior to site authorisation.
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Statistical methods
Sample size
The study was planned to detect a mean change in PBC-40 fatigue domain score of 5 units at 3 months’
follow-up (equating to an average of a 0.5-point change per question, a difference in PBC-40 score
demonstrated in our population-based studies to be associated with significantly higher levels of social
function).24 Previous studies had shown a standard deviation (SD) of 8 units and a correlation of 0.6
between baseline and follow-up, so, using a power of 90% and a 5% significance level, this required
outcome data from 35 participants per arm. A total of 78 participants (39 per arm) was planned to be
recruited and randomised, assuming 10% attrition at 3-month follow-up.21
However, as recruitment was slower than expected, even after expanding recruitment beyond the
north-east region of England, a revised sample size calculation was undertaken. Consequently, trial
recruitment was extended by 6 months and the power of the trial was reduced to 80%, with a revised
target sample size (with other estimates of parameters unchanged) of 58 participants (29 per arm). These
changes to the design of the trial were agreed by the funder and submitted as a substantial amendment,
which was accepted by both the Research Ethics Committee (REC) and MHRA during October 2015.
Statistical analysis
A complete statistical analysis plan was finalised and signed before datalock and unblinding (see Report
Supplementary Material 1). It provides full details of statistical analyses, variables and outcomes.
All analyses were performed on the intention-to-treat (ITT) population. A pragmatic ITT approach was used
in which patient outcomes were reported at their visit nearest the scheduled appointment date. Baseline
characteristics of the study population were summarised separately within each randomised group.
The primary analysis was the PBC-40 fatigue domain. Descriptive statistics were reported at each time
point (baseline and 3, 6, 9 and 12 months) in both arms. PBC-40 fatigue domain scores at 3 months were
compared in the intervention and placebo groups using multiple linear regression with adjustment for
baseline PBC-40 fatigue score, age in years, UK-PBC risk model score at 10 years and patient location
(managed by the Newcastle Clinics for Research and Service in Themed Assessment centre for at least
1 year or not) at baseline. The results were reported as an adjusted difference in means with a 95%
confidence interval (CI). Bootstrap estimation was used throughout. The time course of the comparison
between intervention and control groups over the 12-month follow-up period using the time points above
was assessed for PBC-40 fatigue domain using repeated measures analysis of variance (ANOVA).
The above analyses for PBC-40 fatigue score were repeated for secondary outcomes, namely:
l other PBC-40 domain scores (itch, cognitive, social, emotional and other symptoms)
l clinical symptom and functional capability scales (ESS, OGS, PROMIS HAQ, COGFAIL, HADS and
fatigue diary)
l metric ENMO activity monitoring (daily average and best 5 hours)
l bioenergetics outcomes (minimum pH post exercise, pH recovery half-time, pH fall with exercise,
AUC for pH and anaerobic threshold)
l biological outcomes [serum immunoglobin level (IgG and IgM)].
Euclidian Norm Minus One, bioenergetics and biological outcomes were collected only at baseline and
3 months, so no repeated measures analyses were performed.
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Descriptive analyses were reported for other secondary outcomes listed below [additional repeated
measures (ANOVA up to 12 months) were carried out for bilirubin and serum ALP outcomes]:
l full blood count (haemoglobin concentration, white blood cell count and platelet count)
l liver function test [prothrombin time, bilirubin level, ALP level, ALT level, AST level, albumin level, GGT
level, activated partial thromboplastin time and C-reactive protein (CRP) concentration]
l lipid profile [low-density lipoprotein cholesterol (LDL), high-density lipoprotein cholesterol (HDL)
and triglyceride]
l urea and electrolytes (U&E) (urea, creatinine, sodium and potassium concentrations)
l anti-mitochondrial antibody titre (expressed as number and percentage) and anti-PDC antibody level
l CD19 B-cell depletion.
Change in serum ALP level (at 3 and 12 months from baseline) was also measured and we classified a
drop in level of > 15% or normalisation (within normal range) as being clinically significant. The number
(%) of clinically significant results in each arm was reported.
Mechanistic analyses
Scatterplots and correlations between the change in PBC-40 fatigue domain score over 3 months and
change in five bioenergetics outcomes were produced (see Figure 4).
All statistical analyses were performed using the statistical software package Stata® (version 14.1;
StataCorp LP, College Station, TX, USA).
Safety
Monitoring for safety was undertaken in accordance with GCP. Full details and definitions of AEs, SAEs,
ARs, serious adverse reactions (SARs), unexpected adverse reactions, suspected serious adverse reactions
and SUSARs, as well as severity of AEs and expected ARs, are given in the trial protocol in section 19.1
(https://njl-admin.nihr.ac.uk/document/download/2005806). The local investigator responsible for the care
of the participant was asked to assign causality, in accordance with the study protocol. Causality was
defined as described in section 19.1 (https://njl-admin.nihr.ac.uk/document/download/2005806; accessed
September 2017).
Protocol specifications
For purposes of the specific study protocol:
l All non-SARs were recorded at visits 2–19.
l Any SAEs were recorded throughout the duration of the trial until 12 months after trial therapy was stopped
l The SAEs excluded any pre-planned hospitalisations (e.g. elective surgery) that were not associated with
clinical deterioration.
l The SAEs excluded routine treatment or monitoring of the studied indication that was not associated
with any deterioration in condition.
l The SAEs excluded fatigue (primary outcome measure, already documented and monitored within study).
Adverse reactions during treatment administration
During the infusion, patients were monitored clinically for the onset of clinical features of IRRs (the most
common AEs in rituximab usage). Patients who developed evidence of severe IRRs, especially severe
dyspnoea, bronchospasm or hypoxia, would have had the reaction managed as outlined in Adverse
reactions during treatment administration. In practice, this did not occur.
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Recording and reporting of serious adverse events or reactions
All AEs were reported. Depending on the nature of the event, the reporting procedures below were
followed (or would have been followed if relevant).
Adverse events (including adverse reactions)
All non-SAEs/SARs during drug treatment were reported on the study CRF and sent to the NCTU
management team within 2 weeks to be entered into the MACRO database. Severity of AEs will be
graded on a five-point scale (mild, moderate, severe, life-threatening, causing death). Any relationship
between the AE and the treatment was assessed by the investigator at the site. The investigator at the site
was responsible for managing all AEs/ARs according to the local protocol.
Serious adverse events and reactions (including suspected unexpected serious
adverse reactions)
All SAEs, SARs and SUSARs during drug treatment were reported to the chief investigator within 24 hours
of the site being notified of its occurrence. The initial report was made by via the secure fax to e-mail
reporting system (Soho66, Sunderland UK), which generates a copy for the chief investigator, trial
manager, senior trial manager and sponsor. In the case of incomplete information at the time of initial
reporting, all appropriate information was provided as follow-up as soon as this became available. The
relationship between the SAE and the treatment was assessed by the investigator at the site, as was the
expected or unexpected nature of any SARs.
The MHRA and main REC were to be notified by the chief investigator or NCTU (on behalf of the sponsor)
of all SUSARs occurring during the study in accordance with the following time lines: fatal and
life-threatening within 7 days of notification, and non-life-threatening within 15 days. No SUSARs,
however, occurred.
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Chapter 3 Results
Participant flow
Figure 2 shows the Consolidated Standards of Reporting Trials (CONSORT) flow diagram giving details of
recruitment, randomisation and retention in the trial.
Recruitment
(n = 71)
Randomisation
(n = 57)
Rituximab
(n = 29)
3-month assessment complete
(n = 27)
6-month assessment complete
(n = 27)
9-month assessment complete
(n = 26)
12-month assessment complete
(n = 24)
3-month assessment complete
(n = 28)
6-month assessment complete
(n = 28)
9-month assessment complete
(n = 28)
12-month assessment complete
(n = 26)
Placebo
(n = 28)
• Withdrawn, n = 1
• Died, n = 0
• Lost to follow-up, n = 1
• Withdrawn, n = 0
• Died, n = 0
• Lost to follow-up, n = 0
• Withdrawn, n = 0
• Died, n = 0
• Lost to follow-up, n = 1
• Not due 12-month
   assessment, n = 2a
• Withdrawn, n = 0
• Died, n = 0
• Lost to follow-up, n = 0
• Withdrawn, n = 0
• Died, n = 0
• Lost to follow-up, n = 0
• Withdrawn, n = 0
• Died, n = 0
• Lost to follow-up, n = 0
• Withdrawn, n = 0
• Died, n = 0
• Lost to follow-up, n = 0
• Not due 12-month
   assessment, n = 1a
• Withdrawn, n = 0
• Died, n = 0
• Lost to follow-up, n = 1
• Not yet due randomisation, n = 0
• Withdrawn, n = 6
• Died, n = 1
• Screen fail, n = 7
FIGURE 2 Recruitment flow chart. a, Trial was terminated early on 12 September 2016, so these patients forwent
their 12-month follow-up visits that were due after this date.
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Recruitment
The trial opened to recruitment on 1 October 2012, but due to slower than expected recruitment a no cost
extension was obtained, resulting in the trial closing to recruitment on 1 October 2015 (Figure 3). The
original target recruitment number was 78 participants, but this was later revised to 58 when recruitment
was slower than expected. Seventy-one participants were recruited into the trial, but only 57 were
randomised due to seven screen failures, six withdrawals and one death; the last patient was randomised
on 18 November 2015. Rates of attrition were low, with 50 participants staying in the trial for the full
12 months’ follow-up: 55 provided outcome data at 3 and 6 months and 54 provided outcome data at
9 months, with two participants being lost to follow-up and one withdrew. The trial was terminated early
on 12 September 2016 following consultation with the MHRA and REC and with the endorsement of the
DMEC and TSC. This early termination enabled the final analysis to start once all the 9-month follow-up
data were complete, to meet the final draft report submission deadline. The early termination of the trial
had no effect on the primary end point of the trial, which was measured at 3 months. It might have had an
impact on the secondary objective of the trial, which was to look for any sustained effect of rituximab;
however, the chief investigator did not foresee any impact as being significant, as it was anticipated that
any sustained effects of rituximab would have worn off after 6 months, as seen in other indications
(i.e. RA).38 For this reason, three participants forwent their final 12-month follow-up visit and finished the
study early after their 9-month follow-up visit.
Numbers analysed
Primary outcome analysis was performed on 29 patients in the rituximab group and 28 patients in the
placebo group, with all participants remaining in their original randomisation groups. Some of the
secondary outcome and additional analyses (in particular physical activity and fatigue diary, and muscle
bioenergetics, respectively), were performed on smaller numbers because of issues with usability of the
data (MR-based bioenergetics and physical activity monitoring) and patient compliance of a sufficient level
to meet assessment duration requirements (fatigue diaries and physical activity monitoring).
Data were analysed using a pragmatic ITT approach throughout. A sensitivity analysis for a compliant ITT
(± 1 week at visit 16 at 3 months) for the primary outcome was additionally specified. No participants
completed their PBC-40 questionnaire, which included the primary fatigue domain outcome, within 83–97 days
from the date of randomisation. When the more appropriate time between first infusion at visit 2 to completion
of the PBC-40 questionnaire at 3 months was used, only 17 out of 55 participants had completed primary
outcome questionnaire data within a week of the primary outcome collection target date. However, departures
from this were generally quite small, with an overall median of 9 days in the combined arms [interquartile range
(IQR) 7–15 days, range 0–29 days] from the due date, and similar between arms. The compliant ITT subgroup
analysis was not performed because of the small numbers of those who were compliant (17/55 participants),
even using the less stringent infusion time point rather than randomisation date.
Outcomes and estimation
Baseline data
The baseline clinical data are outlined in Tables 1 and 2. The study population was predominantly female, in
keeping with the established demographic profile of PBC.12 The distribution of UK-PBC risk score data at
baseline suggested a low overall risk, in keeping with the established observation that fatigue severity in PBC is
unrelated to the severity of underlying disease. Participants were predominantly of white ethnicity and most
were not current smokers. More than two-thirds of participants had been managed at Newcastle Clinics for
Research and Service in Themed Assessment centre for at least 1 year. The median age was ≈54 years and
typical body mass index scores were relatively high, indicating that there were some potentially overweight
participants in each arm. Alcohol consumption was modest in both arms and well below the recommended
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weekly intake. The distributions were well balanced between the intervention and control arms, with the
exception of the proportion of UDCA responders and UK-PBC risk score at 10 years prediction.
Primary outcome
Data for the primary outcome, fatigue severity assessed at 3 months using the PBC-40 fatigue domain,
are summarised in Table 3. The primary comparison was at 3 months, in which the mean PBC-40 fatigue
scores were 36.2 in the rituximab arm and 38.1 in the placebo arm. This represents a decrease in score
from baseline of around 5 units in each arm. The unadjusted mean PBC-40 fatigue score was 1.9 units
lower in the rituximab arm at 3 months, but when the distribution of covariates was taken into account,
the adjusted mean difference was –0.9 (95% CI –4.6 to 3.1). Although the 95% CIs are wide, they do not
extend beyond the clinically important difference of 5.
There was little difference in mean fatigue scores between trial arms at any of the time points. The time
course of the comparison between the intervention and control arms over the 12-month follow-up period
TABLE 2 Baseline continuous characteristics by trial arm
Continuous variable
Trial arm
Rituximab (N= 29) Placebo (N= 28)
n Median (IQR) Range n Median (IQR) Range
Age (years) 28 55.9 (48.8–60.0) 34.0–66.7 27 53.3 (49.9–58.8) 39.2–72.1
Alcohol consumption
(units per week: drinkers)
17 4 (2–8) 1–12 9 4 (2–12) 1–14
Alcohol consumption
(units per week: all)
29 1 (0–4) 0–12 28 0 (0–1.5) 0–14
Body mass index (kg/m2) 29 28.7 (24.5–30.5) 19.8–40.5 28 26.7 (22.9–30.7) 18.7–43.5
UK-PBC risk score at 10 years 25 1.26 (0.94–1.74) 0.21–3.55 27 1.75 (1.12–3.04) 0.20–12.90
TABLE 1 Baseline categorical characteristics by trial arm
Categorical variable
Trial arm, n (%)
Rituximab (N= 29) Placebo (N= 28)
Sex: female 28 (96.5) 27 (96.5)
Ethnicity
White 28 (96.5) 28 (100)
Non-white 1 (3.5) 0 (0)
Smoking status
Never 16 (55) 12 (43)
Past 7 (24) 8 (28.5)
Current 6 (21) 8 (28.5)
Managed by the Newcastle Clinics for Research and Service in Themed Assessment centre for at least 1 year
Yes 20 (74) 19 (68)
UDCA use: yes 24 (89) 27 (96.5)
If yes: responder 19 (79) 16 (59)
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was assessed for the primary outcome (PBC-40 fatigue domain) using repeated measures ANOVA at the
time points of baseline and 3, 6, 9 and 12 months. There was no significant difference between the two
trial arms (F = 1.81; p = 0.18) or in the interaction between arms over time (F = 0.41; p = 0.80).
Secondary outcomes
The prespecified secondary outcome data are presented in the following sections by category.
Immunological
Immunological analyses suggested that rituximab was effective in mediating depletion of B-cells, its
primary proposed mode of action. Virtually complete B-cell depletion was seen in all rituximab-treated
patients by the 3-month assessment point (Table 4). Assessment was through CD19, a surface marker
distinct from the molecular target for the drug (CD20), excluding treatment-related surface marker change
following drug action as an explanation. No depletion was seen in the placebo arm. Complete depletion
was maintained at 6 months, with gradual repopulation to 50% of the baseline level by 12 months. These
kinetics for cell numbers are in keeping with previous reports of rituximab therapy.54,55 The kinetics of
fatigue reduction in the rituximab group mirrored the kinetics of B-cell depletion and recovery. However, in
the placebo group the improvement in fatigue score was not mirrored with similar changes in kinetics of
B-cell depletion and recovery.
Distribution of AMA titre outcome is given in Table 5. Reduction in the levels of anti-PDC antibody (the
characteristic autoantibody of PBC) was also seen in the rituximab (but not the placebo) arm (Tables 5
and 6). Although reduction was seen at 3 months, peak reduction was seen at 6 months and sustained at
9 months. This correlates with the known mechanistic effects of rituximab.
A reduction in IgM fraction was seen at 3 months in the rituximab arm (Table 7). There was a small
reduction in total Ig and IgG levels in the rituximab-treated group and to a lesser extent in the placebo arm.
The incomplete nature of antibody depletion in contrast to the complete depletion of B-cells is in keeping
with previous reports54,55 of rituximab therapy. The known cellular targeting (CD20) expression is seen at a
much lower level in plasma cells than in earlier lineage B-cells, leading to more effective depletion of the latter.
TABLE 3 The PBC-40 fatigue domain score at different time points by trial arm
Time
point
Trial arm
Difference in PBC-40
(scale range 11–55)
fatigue domain
score at 3 months
[adjusted difference
in meansb
(rituximab – placebo)
(95% CI)]
Rituximab Placebo
n
Mean PBC-40
(scale range
11–55) fatigue
domain scorea
(SD)
Range in
PBC-40 (scale
range 11–55)
fatigue
domain score n
Mean PBC-40
(scale range
11–55) fatigue
domain scorea
(SD)
Range in
PBC-40 (scale
range 11–55)
fatigue
domain score
Baseline 29 41.2 (5.5) 32–54 28 43.0 (5.9) 31–54 –0.9 (–4.6 to 3.1)
3 months 27 36.2 (8.4) 14–52 28 38.1 (8.7) 17–51
6 months 27 36.6 (7.6) 19–51 28 39.9 (7.5) 18–54
9 months 25 38.1 (8.3) 20–53 28 39.6 (8.6) 17–55
12 months 23 39.5 (8.2) 26–54 26 39.5 (6.5) 30–53
Repeated measures ANOVA up to 12 months between:
Trial arms: F-test (p-value) 1.81 (0.18)
Arms × time points: F-test (p-value) 0.41 (0.80)
a Unadjusted comparison of means.
b 95% CI for adjusted mean difference with adjustment for baseline measurements.
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Additional patient-reported outcome measures
Additional PROMs were used to assess other aspects of the patient experience (the five non-fatigue
domains of the PBC-40 addressing cognitive, emotional, social and mixed symptoms along with itch),
the ESS (daytime somnolence), OGS (autonomic dysfunction), COGFAIL (cognitive symptoms), HADS
(depression and anxiety) and fatigue diary scores (Table 8). The unadjusted questionnaire score means
showed little difference between trial arms at 3 months and, when the distribution of covariates was
taken into account, there was still little or no difference between mean questionnaire scores. The 95% CIs
were generally wide but there was no suggestion that the results were consistent with any clinically
important differences.
Two observations are, however, worthy of note. In contrast to fatigue, in which some improvement over
time was seen in both the rituximab and placebo arms, no improvement in the other measures was seen in
either group. Any placebo effect was therefore restricted to fatigue, being absent even from the closely
linked cognitive symptom domain. The second observation is that the mean ESS levels (12.3 and 13.3 at
baseline in the two groups) were very high, showing a high level of sleep disturbance suggestive of central
fatigue.
TABLE 5 Anti-mitochondrial antibody titre categories at 3 months by trial arm
Time point, AMA titre category
Trial arm, n (%)
Rituximab Placebo
Baseline
40 1 (5) 1 (5)
80 1 (5) 1 (5)
160 2 (9) 1 (5)
320 3 (14) 7 (33)
> 640 15 (68) 11 (52)
3 months
40 2 (11) 1 (6)
80 0 (0) 2 (12)
160 4 (21) 0 (0)
320 5 (27) 4 (24)
> 640 8 (42) 10 (59)
TABLE 6 Anti-PDC antibody levels up to 12 months by trial arm
Time point
Trial arm
Rituximab Placebo
n
Mean % from
baseline (SD)
Range in %
from baseline n
Mean % from
baseline (SD)
Range in %
from baseline
3 months 27 70.4 (18.0) 29.5–101.5 28 92.6 (12.5) 60.9–110.3
6 months 26 54.4 (21.6) 12.9–93.2 28 96.7 (15.2) 45.5–124.8
9 months 25 59.9 (24.1) 14.9–121.4 28 99.5 (15.3) 61.8–140.9
12 months 24 78.5 (29.0) 22.2–144.4 26 102.2 (21.6) 77.6–186.3
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Physical activity
Physical activity in the study group was assessed using wrist accelerometry, with values derived over
a minimum of 5 days for the overall mean activity and the best 5-hour period (Table 9). There were
considerable missing data in each arm [there were 16/57 (28%) and 23/55 (42%) participants with missing
data at baseline and 3 months, respectively]. Missing data were typically a result of patients not wearing
the activity monitor for sufficient time during the assessment period. ENMO outcomes differed little
between arms at 3 months, but the exercise parameters were slightly higher in the rituximab arm at
baseline. After adjustment for baseline values, the mean exercise parameters were slightly lower in the
rituximab arm, but there was little indication of a large and meaningful difference.
Bioenergetics
We used a combination of MR spectroscopy of muscle and anaerobic threshold assessment using CPET to
calculate changes in pH and recovery time post exercise (Table 10).
In keeping with previous reports,47 anaerobic threshold at baseline was low in the PBC patient group. The
mean values rose in the rituximab arm from baseline to 3-month follow-up, with no change in the placebo
arm. The anaerobic threshold score at 3 months was higher in the rituximab arm than in the placebo arm,
which was also the case after adjustment for baseline values (adjusted difference 1.41, 95% CI 0.03 to 2.80).
In keeping with our previous reported findings, although muscle pH values at rest were within the normal
range, the minimum pH following the specific exercise task was highly variable among the PBC patients,
with substantial acidosis seen in some patients. Minimum pH in muscle seen following exercise was slightly
higher at 3 months than at baseline, but this was seen in both trial arms. No reduction in the time taken
to recover to baseline pH after exercise and no reduction in the AUC for pH (a factor combining the
degree of acidosis and the length of time taken to recover to the baseline level and an estimate therefore
of degree of muscle intracellular acid exposure) were seen in either trial arm. Comparison of bioenergetics
outcomes between trial arms shows that the adjusted differences in means at 3 months were all small with
relatively narrow 95% CIs for the pH parameters; however, the 95% CI was wide for the comparison
of AUC.
TABLE 9 Euclidian Norm Minus One outcomes at baseline and 3 months by trial arm
Time point
Trial arm
Difference at 3 months
[adjusted difference in
means (rituximab – placebo)
(95% CI)b]
Rituximab Placebo
n
Mean (SD)
ENMO
outcomea
Range in
ENMO
outcome n
Mean (SD)
ENMO
outcomea
Range in
ENMO
outcome
Baseline (pre)
Average ENMO 18 26.7 (4.8) 19.6–36.7 23 24.5 (7.6) 14.0–46.7 N/A
ENMO best 5 hours 18 51.6 (11.6) 34.6–70.6 23 46.6 (16.9) 24.9–95.3 N/A
3 months (post)
Average ENMO 16 25.3 (4.9) 17.2–33.8 16 25.3 (7.7) 12.4–43.2 –1.19 (–3.44 to 1.23)
ENMO best 5 hours 16 47.8 (10.8) 34.3–73.5 16 46.0 (15.3) 18.0–80.2 –1.33 (–6.04 to 3.09)
N/A, not applicable.
a Unadjusted comparison of means.
b 95% CI for adjusted mean difference with adjustment for baseline ENMO measurements.
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Plots of the changes in bioenergetics outcomes against changes in fatigue scores are shown in Figure 4
and the correlations are given in Table 11. The changes were frequently close to zero, with the exception
of the anaerobic threshold: there were more non-zero changes in the rituximab arm, but these were not
consistently in one direction. The correlation coefficients were all close to zero. There was little evidence
that improved fatigue scores are associated with better bioenergetics outcomes. However, sample sizes in
each arm were small and correlations of combined arms are based on just 41–45 participants, depending
on outcome measure.
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FIGURE 4 Change in muscle bioenergetics outcomes compared with change in fatigue score. (a) Change in
minimum pH post exercise; (b) change in AUC; (c) change in recovery time; (d) change in pH post exercise; and
(e) change in anaerobic threshold.
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TABLE 11 Correlations (Pearson’s r) between changes in PBC-40 fatigue domain score and changes in bioenergetics
outcomes by trial arm
Change in PBC-
40 fatigue score,
correlation with:
Trial arm
OverallRituximab Placebo
n Correlation 95% CI n Correlation 95% CI n Correlation 95% CI
Minimum pH post
exercise
18 0.034 –0.440 to
0.493
23 –0.062 –0.463 to
0.359
41 –0.013 –0.319 to
0.296
pH fall with
exercise
18 –0.044 –0.501 to
0.432
24 0.065 –0.347 to
0.457
42 0.011 –0.294 to
0.314
Recovery time
(seconds)
18 –0.443 –0.754 to
0.030
23 –0.059 –0.460 to
0.362
41 –0.194 –0.474 to
0.121
AUC for pH 18 –0.082 –0.529 to
0.400
24 0.075 –0.338 to
0.465
42 –0.007 –0.310 to
0.297
Anaerobic
threshold
23 –0.119 –0.507 to
0.308
22 0.416 –0.006 to
0.713
45 0.117 –0.183 to
0.396
RESULTS
Ancillary?analyses
Impact?on?biochemical?disease?parameters
The?B-cell-depleting?therapy?(RITuximab)?as?a?treatment?for?fatigue? in?Primary?Biliary?Cirrhosis?(RITPBC)?
trial?was?not?designed?or?powered?to?explore?the? impact?of?the?drug?on? liver? injury.?The?cohort?of?treated?
patients,?however,?exceeds?the?total?world?experience?of?PBC?patients?treated?with?biological?agents?to?
date.?Furthermore,?because?the?primary?target?was?fatigue,?a?non-stage-associated?symptom,?treated?
patients?were?typically?early? in?the?disease?course.?This?contrasts?with?other?trials?of?biological?agents,?
which?have?typically?been?performed? in?patients?with?advanced/aggressive?disease.?The?RITPBC?trial?
therefore?presents?a?unique? insight? into?the? impact?of?rituximab?therapy? in?early?disease,?which?could?
inform?future?trials?of?disease-modifying?therapy.? It? is?for?this?reason?that?the?biochemical?results?are?
reported? in?Tables?12–15.
Baseline?biochemical?parameters?were?typical?of?early-stage?PBC,?with?median?ALP?values?of?136? ?l?and?
131? /l?in?the?rituximab?and?placebo?groups,?respectively.?Subsequent?to?the?design?of?the?trial,?definitions?
have?been?developed?for?the?risk?status?for?PBC?patients.?These?include?dichotomous?scoring?systems
such?as?the?Toronto?Criteria?and?continuous?variable?scoring?systems?such?as?the?UK-PBC?risk?score.4,62?Over?
the?12-month?period?of?assessment?in?the?placebo?group,?a?typical?PBC?natural?history?pattern?was?seen,?
with?small?increases?in?the?ALT?and?bilirubin?levels?(the?latter?of?which?were?within?the?normal?range).?There?
were?no?significant?differences?between?trial?arms?or?in?the?interaction?between?arms?over?time?in?repeated?
measure?ANOVA?up?to?12?months?for?bilirubin,?but?there?were?significant?differences?between?trial?arms
(F?=?6.17;?p?=?0.016)?and?in?the?interaction?between?arms?over?time?(F?=?2.91;?p?=?0.023)?for?ALP?outcome?
(see?Tables?12?and?13).
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Median?ALP?level?fell?from?136? ???to?106? /l?over?3?months?in?the?rituximab?arm,?whereas?the?median?ALP?
level?rose?from?????????to?137? ???in?the?placebo?arm.?Ninety-three?per?cent?of?patients?in?the?rituximab?
arm?had?a?normal?ALP?level?at?3?months,?compared?with?65%?in?the?placebo?arm?(Table?16).?All?
parameters?progressively?returned?to?baseline?levels?by?12?months?of?follow-up.
There? were? no? notable? differences? between? the? rituximab? and? placebo? arms? for? any? lipid? parameters,?
creatinine? concentration? or? serum? electrolyte? levels? or? any? change? from? baseline? measurements? up? to
12?months?(see?Tables?14?and?15).
Safety
There?were?four?SAEs?during?the?course?of?the?trial,?all?of?which?were?unrelated?to?treatment?(Table?17).?
There?was?one?death?from? lobar?pneumonia?and?chronic?obstructive?pulmonary?disease,?which?occurred?
after?consent?but?prior?to?baseline?visit.?This?participant?did?not?receive?any? intervention.?One?participant?in?
the?placebo?arm?was?hospitalised?for?right?optic?neuritis?and,?owing?to?concerns?that?this?might?be?
treatment?related,?emergency?unblinding?was?carried?out.?This?same?participant?was?hospitalised?for
left?optic?neuritis?at?a? later?date,?but?made?a?full?recovery?on?both?occasions.?One?participant? in?the?
placebo?group?with?a?background?of?chronic?abdominal?pain?was?hospitalised?for?abdominal?pain,
but?subsequently?made?a?full?recovery?after?being?treated?with?opiates.
Severe?adverse?events
For?SAEs,?we?collected? information?on?the?number?of?patients? in?each?trial?arm?who?experienced?an?event?
and?the?number?of?patients?assessed?(see?Table?17).
TABLE?16? Proportion?of?patients?with?clinically?significant?ALP?level?and?those?in?the?normal?range?by?trial?arm
ALP
Trial arm, n (%)
Rituximab Placebo
Clinically significant 15% drop in ALP from baseline
3 months (N= 55) 18 (67) 4 (14)
12 months (N = 49) 8 (33) 2 (8)
Patients with ALP in normal rangea
Baseline (N= 57) 21 (78) 17 (61)
3 months (N= 55) 25 (92.5) 18 (64.5)
12 months (N = 49) 20 (77) 17 (65.5)
Patients with ALP in normal range or with 15% drop from baseline
3 months (N= 55) 25 (92.5) 19 (68)
12 months (N = 49) 20 (83.5) 17 (68)
a?Normal?range?for?ALP?is?between?30??/l?and?130??/l;?applying?Toronto?Criteria?for?response?[≤?1.67?×?upper?limit?of
normal?(130? /l)?giving?a?value?of?217],?the?range? in?these?fatigued?patients? is?40–217?or?15%?drop?at?3?months?from?
baseline? level.
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Chapter 4 Discussion
Summary of main findings
Fifty-seven eligible participants aged ≥ 18 years with PBC and moderate or severe fatigue (PBC-40 fatigue
domain score of > 33) were randomised to rituximab or placebo, and trial attrition was very low. Rituximab
was found to be safe in this patient group, with no disease-attributable SAEs.
Immunological analyses showed that rituximab was effective in mediating depletion of B-cells, as expected.
However, there was no statistically significant difference in the primary outcome (mean PBC-40 fatigue
score at 3 months) between the rituximab and placebo arms (adjusted mean difference –0.9, 95% CI –4.6
to 3.1); improvement in mean PB-40 fatigue score was observed at 3 months in both arms.
There were no significant differences in secondary outcomes at 3 months, covering patient-reported,
immunological, exercise and bioenergetics outcomes, except for in anaerobic threshold and immunoglobin
serum levels (IgG and IgM), which improved with rituximab but not placebo. Overall, there was no evidence
to support the use of rituximab as therapy for the treatment of fatigue in this group of patients.
Strengths
Levels of patient interest were high, as was retention within the study, both indicating a high degree of
patient acceptability. This experience mirrors that of recent trials targeting itch as a symptom and supports
the view that trials of therapy targeting symptoms in PBC are deliverable and highly acceptable to patients.64
Over a period of 1 year, rituximab was found to be safe. No SAEs were observed in the study participants
who received the active drug (compared with three in the placebo group). In particular, no worsening of
liver function was observed. This is in keeping with other reports of the agent in PBC and in contrast to
the observation of worsening of liver function in murine models of PBC treated with anti-CD20.54,55,65 This
divergence of effects is likely to reflect the limitations of current murine models of PBC and challenges their
relevance to therapeutics development. We believe that the observation of a benign safety profile (within
the constraints of a 1-year follow-up study) will be informative both for the use of rituximab in other related
liver disease (most obviously immunoglobulin G4 disease) and in the development of future biological
therapy strategies in PBC.
Limitations
Recruitment fell short of the original target. Although levels of patient interest were high, and numbers of
patients with potential eligibility-matched pre-trial estimates, a significant number of people were lost at
the pre-screening point. This was largely due to exclusion criteria related to potential chronic infection and
malignancy, which were frequently met in a chronic disease population typically aged in their mid-50s.
Although patients affected did not typically exhibit overt chronic infection malignancy, ‘soft’ findings
meant that such processes could not be excluded to a sufficient degree to allow randomisation. We had
estimated a likely exclusion rate on the basis of ‘actual’ criteria rates and had not anticipated the scale
of ‘potential’ exclusion criteria. This issue has important implications for the design of future trials of
biological therapies in PBC. A further issue was visit burden, which is an emerging challenge in PBC trials.
This is particularly an issue with younger patients who are either working or have young families. Emerging
data from the UK-PBC programme suggest that both symptom severity and risk of non-response to
primary therapy are increased in younger patients, making them an important target population for clinical
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trials. This will be an important issue to address when designing future trials in PBC. We do not feel that
the shortfall in recruitment materially altered the outcome of the trial.
Issues were encountered with a number of the secondary outcome measures (in particular MR-based
muscle bioenergetics, physical activity monitoring and fatigue diaries). Data sets were incomplete for these
measures because of either issues of compliance (fatigue diaries and physical activity monitoring for which,
despite instructions emphasising the importance of the time span for data capture, insufficient data were
retrieved for some patients to allow inclusion in the analysis) or analysis (MR-based muscle bioenergetics
and physical activity monitoring where extraction of reliable, usable data issues of not possible for some
completed assessments). The reliability of data capture limits their utility in trials of fatigue and its
mechanisms. Further work is needed on these measures before they can be reliably used as trial outcome
measures as opposed to experimental study methodologies.
Interpretation
This was the first trial of any liver disease in which the primary treatment target was fatigue and its impact
on quality of life. No difference was found in the primary outcome between arms, so there is no evidence
to support the use of rituximab as a treatment for fatigue in otherwise unselected PBC patients with
moderate to severe fatigue. B-cell depletion was complete in all the rituximab-treated patients, excluding a
technical drug failure as an explanation for this finding, with progressive reconstitution over the year of
follow-up (although the baseline level was not reached by the 12-month final assessment point).
A mean reduction of 5 units in the fatigue domain of the PBC-40 (the predefined level for a clinically
significant fall) was observed in both the active and placebo drug groups. This remained present at
6 months, with a gradual increase, almost back to baseline levels, by 12 months. Within the trial arms,
16 out of the 27 (59%) rituximab-treated and 10 out of the 28 (36%) placebo-treated participants
showed a 5-point or greater fall in fatigue scores. Potential explanations for the apparent reduction in
fatigue severity in the placebo arm include a significant placebo effect and regression to the mean. The
lack of beneficial effect on physical activity level, an objective measure that has relevance to the subjective
domain of fatigue and which correlates in PBC with fatigue severity, would provide support for the view
that there is no significant fatigue improvement with rituximab in PBC. Interestingly, the degree of
response seen in the placebo group (36%) mirrors that seen in the placebo arm in recent trials of novel
antipruritic therapy in PBC, suggesting that this may represent a natural placebo response rate in this
symptomatic condition.64 This observation will help with the design of future studies of symptomatic
therapy in the condition. It is striking that any change in levels of patient-reported outcomes was restricted
to the primary outcome parameter, namely fatigue. No change over time was seen in the closely linked
cognitive domain of the PBC-40, or even in the itch domain (a parameter previously demonstrated to be
susceptible to placebo effect in trials of antipruritic therapy). It is also interesting to observe that the
restriction of a placebo effect to the primary outcome symptom seen in this trial is mirrored in recent trials
of antipruritic therapy, in which a placebo effect was seen for pruritus severity but not fatigue.64 One
approach to mitigating the placebo effect in future trials in PBC might therefore be to make the target
more generic (‘symptom burden’ rather than a specific symptom). The very specific nature of the placebo
effect does also raise the question of whether or not psychological interventions may have a value in at
least mitigating the impact of symptoms in individual patients.
The variability in the apparent response to rituximab was significant, with some recipients exhibiting
almost complete resolution in their fatigue and others showing no change. Although this could represent
a further manifestation of a placebo effect, it also raises the possibility that fatigue is heterogeneous in
nature and that only a subgroup of patients, with a particular form of the disease, are responders to
rituximab. Since the design of the trial, it has become clear that a stratified approach to therapeutics in
PBC is highly effective (the advent of targeted second-line therapy has led to recent progress in prognostic
therapy in PBC), something that had previously been thought to be a major challenge when using
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unselected patient approaches.14 The RITPBC trial used an unselected approach that may be a limitation.
Again, subsequent to the design of the trial, it has become increasingly accepted that central and
peripheral fatigue have quite distinct characteristics in PBC.24 The underpinning data and study hypothesis
in the RITPBC trial were based on peripheral muscle abnormality (and peripheral fatigue). The study
population showed, at baseline, significant levels of sleep disturbance [40/53 trial participants (76%) had
baseline ESS scores of ≥ 10] and cognitive impairment, which are features strongly associated with central
fatigue.66,67 There is a need to determine rituximab response in the different fatigue variants in PBC in
order to further understand the biology of this important symptom in different endotype groups in order
to inform future trials of fatigue-modifying therapy in PBC. We do not believe that there is, at present, any
rationale for further trials of rituximab.
Significant bioenergetic abnormality was seen at baseline in the participants, mirroring the findings in the
original studies that informed the trial.39,40 Although resting muscle pH was normal, the minimum pH seen
following exercise was again dramatically (but variably) lowered. The time for recovery to the baseline
level was again prolonged. Rituximab therapy was associated with a small rise in post-exercise muscle pH
(and a small fall in the pH drop with exercise); however, this effect was not significant. Recovery time
was not affected (in keeping with a model in which it is autonomic regulation of muscle blood flow and
proton efflux from acidotic muscle cells, neither of which would be predicted to change with rituximab
therapy). Similarly, the AUC for total muscle acid exposure, which is driven to a significant degree by pH
recovery time, was not improved by rituximab therapy. In contrast to muscle bioenergetic function on MR,
anaerobic threshold, which was again found to be low in the PBC group, mirroring earlier observations,
improved significantly with rituximab (but not placebo), with a degree of change that was biologically
significant. Serum anti-PDC antibody levels were significantly reduced with rituximab, although the
antibody remained present at lowered levels.47 This is in keeping with previous reports of the use of
rituximab in PBC and in other disease states, and with the cellular distribution of CD20 (it is present on
B-cells but not plasma cells). Peak depletion of anti-PDC antibody was seen at 6 months rather than
the 3-month primary end point. In terms of the bioenergetic model for fatigue in PBC, a number of
conclusions can be drawn. The first is that the previously described bioenergetic abnormality is confirmed
in this study in a cohort of highly fatigued patients. The second is that anaerobic threshold impairment
is reduced in patients who exhibit depletion of anti-PDC antibodies. Further analysis will be required to
determine whether or not this link is causal; however, the finding would be at least in keeping with the
hypothesis that anti-PDC antibodies have a direct metabolic role in increasing anaerobic metabolism.
If this is indeed the case, it may be that the peak effect has been missed given that the peak in anti-PDC
antibody depletion was at 6 months, 3 months after the last anaerobic threshold assessment. The third
conclusion is that the link between anti-PDC antibodies and anaerobic threshold, and between muscle
bioenergetic abnormality and perceived fatigue, is limited. Change in post-exercise muscle pH with
rituximab was limited, as was any change in fatigue. The apparent disconnect between anaerobic
threshold, on the one hand, and muscle bioenergetics abnormality on MR spectroscopy, on the other,
would suggest that factors other than the balance between aerobic and anaerobic metabolism play
the predominant role in regulating muscle pH. The obvious candidate would be the capacity of muscle
to handle protons and lactate: capacity that may be modified by addressing autonomic dysfunction
(highly prevalent in PBC and postulated to impact on both transport of protons and lactate out of muscle
cells and vascular outflow from muscle tissue) or through exercise therapy (which is known to increase
proton/lactate transporter levels and to increase vascular outflow). There is evidence, albeit very limited,
to suggest the efficacy of both approaches in PBC.40,68
This study was not designed or powered to explore the impact on rituximab on liver disease severity in
PBC. In the course of the study, however, it became clear that the information that could be derived would
be useful in assisting in the design of future studies of disease-modifying drugs. There has been recent
advance in the treatment of PBC, with second-line therapy being approved for use in patients showing
inadequate response to first-line therapy with UDCA.14 The successful agent, obeticholic acid, is, however,
a modified bile acid and thus represents a more effective version of the UDCA approach. Trials of the
obvious alternative approach, immunotherapy to modify the immune injury to bile ducts that leads to the
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cholestasis in the first place, have, in marked contrast, been unsuccessful.69 One potential explanation for
this lack of efficacy would be that the biological agents may have been used at the wrong point in
the disease pathway, following proven failure of treatment with UDCA (if immune injury is an early
phenomenon, and cholestasis a late one, then failure to respond to UDCA would imply the presence of
‘downstream’ aggressive cholestasis, meaning that only then moving to treatment of ‘upstream’ immune
activity would be counterintuitive). Because the treatment target in the RITPBC trial was fatigue, which is
unrelated to disease severity and UDCA therapy, this trial provides a unique data set relating to use of a
biological agent in patients who have not previously had UDCA therapy.19,70 As far as we are aware, this is
the only such data set available in the world. Our data strongly suggest that in a cohort of PBC patients
not characterised by UDCA treatment failure, rituximab, in addition to being safe, has a measurable effect
on both individual parameters of disease severity (ALP and ALT levels) and the recently derived UK-PBC,
which is a fully validated predictive model for the disease. Ninety-three per cent of participants in the
rituximab arm had normal liver function at 3 months, compared with 65% of participants in the placebo
arm. These findings might support the concept that rituximab has a beneficial effect on disease activity
when given early in the disease course.
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Chapter 5 Conclusions
The following conclusions can be drawn from this study:
l There is no evidence to support the use of rituximab for the treatment of fatigue in otherwise
unselected populations of PBC patients with moderate to severe fatigue. On average, there was a
5-point reduction in PBC-40 fatigue severity (measured on the PBC-40 fatigue domain) over 3 months
(which was of clinical significance), but this was seen in both trial arms.
l Trials of fatigue-modulating therapy are deliverable in PBC and acceptable to patients (retention was
96.5%). However, there is a significant issue with placebo effects that are similar in scale to those seen
in recent trials of anti-itch therapy.
l Rituximab when used in PBC was safe, with no attributable SAEs.
l The bioenergetics abnormality reported previously in fatigued PBC patients and that underpinned this
trial concept was also seen in this trial.
l Anaerobic threshold was significantly improved by rituximab. Muscle bioenergetics abnormality on
MR spectroscopy was not, however, significantly improved. The capacity of muscle to handle protons
and lactate may therefore play a more important role in fatigue expression than PBC autoantibody.
Future trials of therapy for fatigue might address these aspects (exercise therapy and targeting
autonomic dysfunction).
l Although the trial was not designed or powered to explore impact on liver biochemistry, our findings
point to a positive impact of rituximab on liver function when used in patients not defined by
UDCA failure.
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Patient data
This work uses data provided by patients and collected by the NHS as part of their care and support. Using
patient data is vital to improve health and care for everyone. There is huge potential to make better use of
information from people’s patient records, to understand more about disease, develop new treatments,
monitor safety, and plan NHS services. Patient data should be kept safe and secure, to protect everyone’s
privacy, and it’s important that there are safeguards to make sure that it is stored and used responsibly.
Everyone should be able to find out about how patient data are used. #datasaveslives You can find out
more about the background to this citation here: https://understandingpatientdata.org.uk/data-citation.
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Study discussed, Informed Consent Form signed, 
physical examination given, blood samples taken (if 
applicable), medications recorded. 
 
Quality of Life questionnaires completed, blood samples 
taken, MRI scan performed, exercise capacity assessed, 
physical activity assessed using  two monitors, pregnancy 
test performed (if applicable), fatigue diary issued, 
randomised to receive either Rituximab or placebo infusion, 
changes of medications recorded 
 
First infusion of Rituximab or placebo given, physical 
examination performed, blood samples taken, adverse 
events and changes of medications recorded 
 
Physical examination performed, blood samples taken, adverse 
events and changes of medications 
 
Second infusion of Rituximab or placebo given, physical 
examination performed, blood samples taken, adverse events 
and changes of medications recorded 
Telephone calls by a Research Nurse, adverse events and 
changes of medications recorded 
 
Physical examination performed, Quality of Life 
questionnaires completed, blood samples taken, MRI scan 
performed, exercise capacity assessed, physical activity 
assessed using two monitors, adverse events and changes of 
medications recorded 
 
Physical examination performed, Quality of Life 
questionnaires completed, blood samples taken, adverse 
events and changes of medications recorded 
 
Physical examination performed, Quality of Life 
questionnaires completed, blood samples taken, adverse events 
and changes of medications recorded. Fatigue diary returned 
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Appendix 5 Standard operating procedure for
sample handling
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